

chain nodes :

7 8 9 10 11 12 13 15 16 17 20 28 30 31 32 33 36

ring nodes :

1 2 3 4 5 6 21 22 23 24 25 26

chain bonds :

1-7 4-20 7-8 7-12 7-13 8-15 8-16 9-11 9-10 9-17 16-17 16-30 16-36 20-21  
20-28 31-32 31-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

1-7 4-20 7-8 7-12 7-13 8-15 8-16 9-11 9-10 16-30 16-36 20-21 20-28 31-32  
31-33

exact bonds :

9-17 16-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-26 22-23 23-24 24-25 25-26

isolated ring systems :

containing 1 :

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:H,Cy

G3:H,CH3,[\*1]

Match level :



1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 25:Atom 26:Atom 28:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS  
36:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 H, Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu

G2 H, Cy

G3 H, Me, [01]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 09:13:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 199831 TO ITERATE

100.0% PROCESSED 199831 ITERATIONS

831 ANSWERS

SEARCH TIME: 00.00.05

L2 831 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 09:13:49 ON 23 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Apr 2008 VOL 148 ISS 17  
FILE LAST UPDATED: 22 Apr 2008 (20080422/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12  
L3 51 L2

=> fil reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.48	179.05

FILE 'REGISTRY' ENTERED AT 09:13:56 ON 23 APR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 APR 2008 HIGHEST RN 1016649-50-5  
DICTIONARY FILE UPDATES: 22 APR 2008 HIGHEST RN 1016649-50-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10 series\10824057\2.4.23.2008.str



```

chain nodes :
7 8 9 10 11 12 13 15 16 17 20 28 30 31 32 33 36
ring nodes :
1 2 3 4 5 6 21 22 23 24 25 26
chain bonds :
1-8 4-20 7-13 7-12 7-8 7-16 8-15 9-11 9-10 9-17 16-36 16-17 16-30 20-21
20-28 31-32 31-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-8 4-20 7-13 7-12 7-8 7-16 8-15 9-11 9-10 16-36 16-30 20-21 20-28 31-32
31-33
exact bonds :
9-17 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-26 22-23 23-24 24-25 25-26
isolated ring systems :
containing 1 :

```

G1:H,CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:H,Cy

G3:H,CH3,[\*1]

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 28:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS
36:CLASS



```

L4            STRUCTURE    UPLOADED

$$\Rightarrow d$$

L4 HAS NO ANSWERS

L4 STR



G1 H, Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu

G2 H, Cy

G3 H, Me, [01]

Structure attributes must be viewed using STN Express query preparation.

=> s 14 ful

FULL SEARCH INITIATED 09:14:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6324 TO ITERATE

100.0% PROCESSED      6324 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L5                      0 SEA SSS FUL L4

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

357.41

FILE 'CAPLUS' ENTERED AT 09:14:28 ON 23 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Apr 2008 VOL 148 ISS 17  
FILE LAST UPDATED: 22 Apr 2008 (20080422/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d ibib hitstr 13 1-51

# 10824057 - Compound Search


L3 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:1311129 CAPLUS  
 DOCUMENT NUMBER: 146:62699  
 TITLE: Preparation of polycyclic oxadiazoles or isoxazoles as  
 S1P receptor ligands  
 INVENTOR(S): Albert, Rainer; Weiler, Sven; Zecris, Frederic  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SOURCE: PCT Int. Appl., 53pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006131336	A1	20061214	WO 2006-EP5422	20060607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TD, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, SA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006256968	A1	20061214	AU 2006-256968	20060607
CA 2610310	A1	20061214	CA 2006-2610310	20060607
EP 1893591	A1	20080305	EP 2006-754184	20060607
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2008014009	A	20080213	KR 2007-728641	20071207
PRIORITY APPLN. INFO.:				
GB 2005-11684 A 20050608				
GB 2006-405 A 20060110				
WO 2006-EP5422 W 20060607				

OTHER SOURCE(S): MARPAT 146:62699  
 IT 916805-32-8P 916805-33-9P 916805-34-0P  
 916805-35-1P 916805-36-2P 916805-41-9P  
 916805-49-7P 916805-50-0P 916805-51-1P  
 916805-52-2P 916805-53-3P 916806-73-0P  
 916806-74-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of polycyclic oxadiazoles or isoxazoles as S1P receptor ligands)  
 RN 916805-32-8 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(2,2-dimethylpropoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 916805-33-9 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(2-propyn-1-yloxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916805-34-0 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(2-methylpropoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916805-35-1 CAPLUS  
 CN Alanine, 2-methyl-N-[[4-[5-[4-phenoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 916805-36-2 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(cyclobutylmethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916805-41-9 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(1-methylethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 916805-49-7 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(2-fluoroethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916805-50-0 CAPLUS

23 APR 2008


L3 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN L-Alanine, N-[[4-[5-[4-phenoxy-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916805-51-1 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 916805-52-2 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(3-fluorophenoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 916805-53-3 CAPLUS  
 CN L-Alanine, N-[[4-[5-[4-(2-fluorophenoxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 916806-73-0 CAPLUS  
CN D-Alanine, N-[[4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 916806-74-1 CAPLUS  
CN L-Alanine, N-[[4-[5-[2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:17:23 CAPLUS  
DOCUMENT NUMBER: 145:429214  
TITLE: Self-association of free base porphyrins with aminoacid substituents in AOT reverse micelles  
AUTHOR(S): Andrade, Suzana M.; Teixeira, Catarina; Togashi, Kenisio M.; Costa, Silvia M. B.; Sobral, Abilio J. F. N.  
CORPORATE SOURCE: Centro de Quimica Estrutural, Complexo 1, Instituto Superior Tecnico, Lisbon, 1049-001, Port.  
SOURCE: Journal of Photochemistry and Photobiology, A: Chemistry (2006), 178 (2-3), 225-235  
CODEN: JPPCEL; ISSN: 1010-6030  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 596102-93-1 912562-51-7  
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)  
(self-association of free base porphyrins with aminoacid substituents in AOT reverse micelles)  
RN 596102-93-1 CAPLUS  
CN L-Phenylalanine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis-, tetramethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




L3 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
REFERENCE COUNT: 10  
THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 912562-51-7 CAPLUS  
CN L-Phenylalanine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



## 10824057 - Compound Search

L3 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

Ph

L3 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 2-A



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:1064578 CAPLUS  
DOCUMENT NUMBER: 143:318625  
TITLE: Matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer  
AUTHOR(S): Fujino, Haruhiko; Kondo, Kazuya; Ishikura, Hisashi; Maki, Hideo; Kinoshita, Hidetaka; Miyoshi, Takanori; Takahashi, Yuji; Sawada, Naruhiko; Takizawa, Hiromitsu; Nagao, Taisuke; Sakiyama, Shoji; Monden, Yasumasa  
CORPORATE SOURCE: Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto Tokushima, Japan  
SOURCE: Molecular Cancer Therapeutics (2005), 4(9), 1409-1416  
CODEN: MCTOCP; ISSN: 1535-7163  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI-166  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(matrix metalloproteinase inhibitor MMI-166 inhibits lymphogenous metastasis in an orthotopically implanted model of lung cancer)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:120903 CAPLUS  
DOCUMENT NUMBER: 142:219266  
TITLE: Preparation of isoxazole derivatives having sulfonamide moiety as MMP inhibitors  
INVENTOR(S): Watanabe, Fumihiko; Yoshikawa, Naoki; Tamura, Yoshinori  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 103 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012268	A1	20050218	WO 2004-JP10697	20040728
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GB, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1650199	A1	20060426	EP 2004-748009	20040728
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 20060183770	A1	20060817	US 2006-565948	20060126
PRIORITY APPLN. INFO.:			JP 2003-282354	A 20030730
			WO 2004-JP10697	W 20040728

OTHER SOURCE(S): MARPAT 142:219266


IT 840531-62-6P 840531-63-7P 840531-64-8P  
840531-65-9P 840531-66-0P 840531-67-1P  
840531-68-2P 840531-69-3P 840531-70-6P  
840531-71-7P 840531-72-8P 840531-73-9P  
840531-74-0P 840531-75-1P 840531-76-2P  
840531-77-3P 840531-78-4P 840531-79-5P  
840531-80-8P 840531-81-9P 840531-83-1P  
840531-84-2P 840531-85-3P 840531-86-4P  
840531-87-5P 840531-88-6P 840531-89-7P  
840531-90-0P 840531-93-3P 840531-94-4P  
840531-95-5P 840531-96-6P 840531-98-8P  
840531-99-9P 840532-00-5P 840532-02-7P  
840532-03-8P 840532-04-9P 840532-05-0P  
840532-06-1P 840532-07-2P 840532-08-3P  
840532-09-4P 840532-10-7P 840532-11-8P  
840532-12-9P 840532-13-0P 840532-14-1P  
840532-15-2P 840532-16-3P 840532-17-4P  
840532-18-5P 840532-19-6P 840532-20-9P  
840532-21-0P 840532-22-1P 840532-23-2P  
840532-24-3P 840532-25-4P 840532-26-5P  
840532-27-6P 840532-28-7P 840532-29-8P  
840532-30-1P 840532-31-2P 840532-32-3P  
840532-33-4P 840532-34-5P 840532-35-6P  
840532-36-7P 840532-37-8P 840532-38-9P  
840532-39-0P 840532-40-3P 840532-41-4P  
840532-42-5P 840532-43-6P 840532-44-7P  
840532-45-8P 840532-46-9P 840532-47-0P

# 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

840532-48-1P 840532-49-2P 840532-50-5P  
 840532-51-6P 840532-52-7P 840532-53-8P  
 840532-54-9P 840532-55-0P 840532-56-1P  
 840532-57-2P 840532-58-3P 840532-59-4P  
 840532-60-7P 840532-61-8P 840532-62-9P  
 840532-63-0P 840532-64-1P 840532-65-2P  
 840532-66-3P 840532-67-4P 840532-68-5P  
 840532-69-6P 840532-71-0P 840532-73-2P  
 840532-75-4P 840532-76-5P 840532-77-6P  
 840532-78-7P 840532-79-8P 840532-80-1P  
 840532-81-2P 840532-82-3P 840533-05-3P  
 840533-06-4P 840533-07-5P 840533-08-6P  
 840533-10-0P 840533-12-2P 840533-13-3P  
 840533-14-4P 840533-15-5P 840533-16-6P  
 840533-17-7P 840533-18-8P 840533-19-9P  
 840533-20-2P 840533-21-3P 840533-22-4P  
 840533-23-5P 840533-24-6P 840533-25-7P  
 840533-26-8P 840533-27-9P 840533-28-0P  
 840533-29-1P 840533-30-4P 840533-31-5P  
 840533-32-6P 840533-33-7P 840533-39-3P  
 840533-40-6P 840533-41-7P 840533-42-8P  
 840533-43-9P 840533-44-0P 840533-45-1P  
 840533-46-2P 840533-47-3P 840533-48-4P  
 840533-49-5P 840533-50-8P 840533-51-9P  
 840533-52-0P 840533-53-1P 840533-54-2P  
 840533-55-3P 840533-56-4P 840533-57-5P  
 840533-58-6P 840533-59-7P 840533-60-0P  
 840533-61-1P 840533-62-2P 840533-63-3P  
 840533-64-4P 840533-65-5P 840533-66-6P  
 840533-67-7P 840533-68-8P 840533-69-9P  
 840533-70-2P 840533-71-3P 840533-72-4P  
 840533-73-5P 840533-74-6P 840533-75-7P  
 840533-76-8P 840533-77-9P 840533-84-8P  
 840533-85-9P 840533-86-0P 840533-87-1P  
 840533-88-2P 840533-89-3P 840533-90-6P  
 840533-91-7P 840533-92-8P 840533-93-9P  
 840533-94-0P 840533-95-1P 840533-96-2P  
 840533-97-3P 840533-98-4P 840533-99-5P  
 840534-00-1P 840534-01-2P 840534-05-6P  
 840534-06-7P 840534-07-8P 840534-08-9P  
 840534-09-0P 840534-10-3P 840534-11-4P  
 840534-12-5P 840534-13-6P 840534-15-8P  
 840534-16-9P 840534-17-0P 840534-18-1P  
 840534-19-2P 840534-21-6P 840534-22-7P  
 840534-23-8P 840534-26-1P 840534-27-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (prepn. of isoxazole derivs. having sulfonamide moiety as MMP  
 inhibitors)  
 RN 840531-62-6 CAPLUS  
 CN D-Alanine, N-[[4-[3-(4-phenyl-5-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840531-63-7 CAPLUS  
 CN D-Alanine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.




RN 840531-64-8 CAPLUS  
 CN L-Alanine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.




RN 840531-65-9 CAPLUS  
 CN D-Alanine, N-[[4-[3-(4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



RN 840531-66-0 CAPLUS  
 CN D-Alanine, N-[[4-[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.




RN 840531-67-1 CAPLUS  
 CN L-Alanine, N-[[4-[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.




RN 840531-68-2 CAPLUS  
 CN Alanine, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-2-methyl-

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


(CA INDEX NAME)



RN 840531-69-3 CAPLUS  
 CN Alanine, N-[[4-[3-(4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-2-methyl- (CA INDEX NAME)




RN 840531-70-6 CAPLUS  
 CN D-Valine, N-[[4-[3-(4-phenyl-5-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.



RN 840531-71-7 CAPLUS  
 CN L-Valine, N-[[4-[3-(4-phenyl-5-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)  
 Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840531-72-8 CAPLUS  
CN D-Valine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 840531-73-9 CAPLUS  
CN L-Valine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-74-0 CAPLUS  
CN D-Valine, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840531-77-3 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(1-methylethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840531-78-4 CAPLUS  
CN D-Valine, N-[[4-[3-(4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840531-79-5 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840531-75-1 CAPLUS  
CN L-Valine, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-76-2 CAPLUS  
CN D-Valine, N-[[4-[3-(4-propylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840531-80-8 CAPLUS  
CN L-Valine, N-[[4-[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840531-81-9 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-83-1 CAPLUS  
CN L-Valine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840531-84-2 CAPLUS  
CN D-Valine, N-[[4-[3-(4-chlorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-85-3 CAPLUS  
CN L-Valine, N-[[4-[3-(4-chlorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840531-88-6 CAPLUS  
CN D-Valine, N-[[4-[3-(4-ethylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-89-7 CAPLUS  
CN D-Valine, N-[[4-[3-(2-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-90-0 CAPLUS  
CN D-Valine, N-[[4-[3-(3-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840531-86-4 CAPLUS  
CN D-Valine, N-[[4-[3-(4-bromophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840531-87-5 CAPLUS  
CN L-Valine, N-[[4-[3-(4-bromophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840531-93-3 CAPLUS  
CN D-Valine, N-[[4-[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840531-94-4 CAPLUS  
CN D-Valine, N-[[4-[3-[3-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840531-95-5 CAPLUS  
CN D-Valine, N-[[4-[3-(4-hydroxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840531-96-6 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(methylthio)phenyl]-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840531-98-8 CAPLUS  
CN D-Valine, N-[[4-[3-(2,5-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840531-99-9 CAPLUS  
CN L-Valine, N-[[4-[3-(2,5-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840532-00-5 CAPLUS  
CN D-Valine, N-[[4-[3-(3,4-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-02-7 CAPLUS  
CN L-Valine, N-[[4-[3-(3,4-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840532-03-8 CAPLUS  
CN D-Valine, N-[[4-[3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-04-9 CAPLUS  
CN L-Valine, N-[[4-[3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840532-05-0 CAPLUS  
CN D-Valine, N-[[4-[3-(4-chloro-3-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-06-1 CAPLUS  
CN L-Valine, N-([4-([3-(4-chloro-3-fluorophenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840532-07-2 CAPLUS  
CN D-Valine, N-([4-([3-(3-fluoro-4-methylphenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-08-3 CAPLUS  
CN D-Valine, N-([4-([3-(3,4-dichlorophenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840532-09-4 CAPLUS  
CN D-Valine, N-([4-([3-(3,4-dimethoxyphenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-10-7 CAPLUS  
CN D-Valine, N-([4-([3-(3,5-difluorophenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-11-8 CAPLUS  
CN D-Valine, N-([4-([3-(2-fluoro-4-methoxyphenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840532-12-9 CAPLUS  
CN D-Valine, N-([4-([3-(2,6-difluorophenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-13-0 CAPLUS  
CN D-Valine, N-([4-([3-(2-fluoro-5-methoxyphenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840532-14-1 CAPLUS  
CN D-Valine, N-([4-([3-(4-fluoro-3-methylphenyl)-5-isoxazolyl]phenyl)sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-15-2 CAPLUS  
CN D-Valine, N-[[4-[3-(3-chloro-4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840532-16-3 CAPLUS  
CN D-Valine, N-[[4-[3-(4-fluoro-3-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-17-4 CAPLUS  
CN L-Valine, N-[[4-[3-(1,3-benzodioxol-5-yl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-18-5 CAPLUS  
CN L-Valine, N-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840532-19-6 CAPLUS  
CN D-Valine, N-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-20-9 CAPLUS  
CN D-Valine, N-[[4-[3-(3-chloro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840532-21-0 CAPLUS  
CN D-Valine, N-[[4-[3-(3-bromo-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-22-1 CAPLUS  
CN D-Leucine, N-[[4-(3-phenyl-5-isoxazolyl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-23-2 CAPLUS  
CN L-Leucine, N-[[4-(3-phenyl-5-isoxazolyl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840532-24-3 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-25-4 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-26-5 CAPLUS  
CN D-Leucine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-30-1 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-bromophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-31-2 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-bromophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-32-3 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840532-27-6 CAPLUS  
CN L-Leucine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-28-7 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-chlorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-29-8 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-chlorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840532-33-4 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-34-5 CAPLUS  
CN D-Leucine, N-[[4-[3-(2-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-35-6 CAPLUS  
CN D-Leucine, N-[[4-[3-(3-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)



## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840532-36-7 CAPLUS  
CN D-Leucine, N-[[4-[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-37-8 CAPLUS  
CN D-Leucine, N-[[4-[3-[4-[(trifluoromethyl)thio]phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840532-38-9 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-ethylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-39-0 CAPLUS  
CN D-Leucine, N-[[4-[3-(2,5-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840532-40-3 CAPLUS  
CN L-Leucine, N-[[4-[3-(2,5-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-41-4 CAPLUS  
CN D-Leucine, N-[[4-[3-(3,4-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840532-42-5 CAPLUS  
CN D-Leucine, N-[[4-[3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-43-6 CAPLUS  
CN L-Leucine, N-[[4-[3-(3-fluoro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-44-7 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-chloro-3-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840532-45-8 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-chloro-3-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-46-9 CAPLUS  
CN D-Leucine, N-[[4-[3-(3-fluoro-4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840532-47-0 CAPLUS  
CN D-Leucine, N-[[4-[3-(3,4-dichlorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-48-1 CAPLUS  
CN L-Leucine, N-[[4-[3-(2,6-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-49-2 CAPLUS  
CN D-Leucine, N-[[4-[3-(2-fluoro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840532-50-5 CAPLUS  
CN D-Leucine, N-[[4-[3-(2,6-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-51-6 CAPLUS  
CN D-Leucine, N-[[4-[3-(3,5-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-52-7 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-fluoro-3-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-53-8 CAPLUS  
CN D-Leucine, N-[[4-[3-(3-chloro-4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840532-54-9 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-fluoro-3-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840532-55-0 CAPLUS  
CN D-Leucine, N-[[4-[3-(3,4-dimethoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840532-56-1 CAPLUS  
CN D-Leucine, N-[[4-[3-(1,3-benzodioxol-5-yl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-57-2 CAPLUS  
CN L-Leucine, N-[[4-[3-(1,3-benzodioxol-5-yl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-58-3 CAPLUS  
CN D-Leucine, N-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840532-59-4 CAPLUS  
CN L-Leucine, N-[[4-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-60-7 CAPLUS  
CN D-Leucine, N-[[4-[3-(3-bromo-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-61-8 CAPLUS  
CN D-Leucine, N-[[4-[3-(3-chloro-4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-62-9 CAPLUS

23 APR 2008

## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN L-Isoleucine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-63-0 CAPLUS  
 CN L-Isoleucine, N-[[4-[3-(4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-64-1 CAPLUS  
 CN L-Isoleucine, N-[[4-(3-phenyl-5-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840532-68-5 CAPLUS  
 CN L-Isoleucine, N-[[4-[3-(4-chloro-3-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-69-6 CAPLUS  
 CN D-Methionine, N-[[4-(3-phenyl-5-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-71-0 CAPLUS  
 CN D-Methionine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
 (CA INDEX NAME)

23 APR 2008

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840532-65-2 CAPLUS  
 CN L-Isoleucine, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-66-3 CAPLUS  
 CN L-Isoleucine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-67-4 CAPLUS  
 CN L-Isoleucine, N-[[4-[3-(3,4-difluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
 (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840532-73-2 CAPLUS  
 CN D-Methionine, N-[[4-[3-[4-(1-methylethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840532-75-4 CAPLUS  
 CN D-Methionine, N-[[4-[3-[4-(trifluoromethoxy)phenyl]-5-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840532-76-5 CAPLUS  
 CN D-Tryptophan, N-[[4-(3-phenyl-5-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

# 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840532-77-6 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-78-7 CAPLUS  
CN D-Tryptophan, N-[[4-[3-[4-(1-methylethyl)phenyl]-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840532-79-8 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-methoxyphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840532-82-3 CAPLUS  
CN D-Glutamic acid, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840533-05-3 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 840533-06-4 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



23 APR 2008


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840532-80-1 CAPLUS  
CN D-Aspartic acid, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840532-81-2 CAPLUS  
CN D-Glutamic acid, N-[[4-[3-(4-fluorophenyl)-5-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-07-5 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840533-08-6 CAPLUS  
CN D-Alanine, N-[[4-[5-[4-(methylthio)phenyl]-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840533-10-0 CAPLUS  
CN D-Valine, N-[[4-(5-phenyl-3-isoxazolyl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840533-12-2 CAPLUS  
CN L-Valine, N-[[4-(5-phenyl-3-isoxazolyl)phenyl]sulfonyl]-  
(CA INDEX NAME)

## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840533-13-3 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-14-4 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-15-5 CAPLUS

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-18-8 CAPLUS  
CN L-Valine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-19-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-propylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-20-2 CAPLUS  
CN D-Valine, N-[[4-[5-(4-(1-methylethyl)phenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN D-Valine, N-[[4-[5-[4-(methylthio)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-16-6 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(methylthio)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-17-7 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840533-21-3 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(1-methylethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-22-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-butylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-23-5 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840533-24-6 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-25-7 CAPLUS  
CN D-Valine, N-[[4-[5-(4-chlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840533-26-8 CAPLUS  
CN L-Valine, N-[[4-[5-(4-chlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-27-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-bromophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-28-0 CAPLUS  
CN L-Valine, N-[[4-[5-(4-bromophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-29-1 CAPLUS  
CN L-Valine, N-[[4-[5-(4-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-30-4 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(trifluoromethoxy)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-31-5 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(trifluoromethoxy)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-32-6 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-33-7 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840533-39-3 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-40-6 CAPLUS  
CN D-Valine, N-[[4-[5-(4-chloro-3-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840533-41-7 CAPLUS  
CN L-Valine, N-[[4-[5-(4-chloro-3-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-42-8 CAPLUS  
CN D-Valine, N-[[4-[5-(3-fluoro-4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840533-43-9 CAPLUS  
CN L-Valine, N-[[4-[5-(3-fluoro-4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-44-0 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-dichlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840533-45-1 CAPLUS  
CN L-Valine, N-[[4-[5-(3,4-dichlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-46-2 CAPLUS  
CN D-Valine, N-[[4-[5-(3,5-dimethoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-47-3 CAPLUS  
CN D-Valine, N-[[4-[5-(2-naphthalenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-48-4 CAPLUS  
CN D-Valine, N-[[4-[5-(1,3-benzodioxol-5-yl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-49-5 CAPLUS  
CN L-Valine, N-[[4-[5-(1,3-benzodioxol-5-yl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-53-1 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-difluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-54-2 CAPLUS  
CN L-Valine, N-[[4-[5-(3,4-difluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-55-3 CAPLUS  
CN D-Valine, N-[[4-[5-(3-fluoro-4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


23 APR 2008

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-50-8 CAPLUS  
CN D-Valine, N-[[4-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-51-9 CAPLUS  
CN D-Valine, N-[[4-[5-(2,3-dihydro-5-benzofuranyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-52-0 CAPLUS  
CN L-Valine, N-[[4-[5-(2,3-dihydro-5-benzofuranyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840533-56-4 CAPLUS  
CN D-Leucine, N-[[4-(5-phenyl-3-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-57-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-58-6 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-59-7 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-60-0 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-64-4 CAPLUS  
CN L-Leucine, N-[[4-[5-[4-(1-methylethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-65-5 CAPLUS  
CN L-Leucine, N-[[4-[5-[4-(methylthio)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-66-6 CAPLUS  
CN L-Leucine, N-[[4-[5-[4-(methylthio)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-61-1 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-propylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-62-2 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-propylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-63-3 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(1-methylethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840533-67-7 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-68-8 CAPLUS  
CN L-Leucine, N-[[4-[5-[4-(4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-69-9 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(4-bromophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840533-70-2 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-bromophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-71-3 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-chlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 840533-72-4 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-chlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-73-5 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-74-6 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(trifluoromethoxy)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-75-7 CAPLUS  
CN L-Leucine, N-[[4-[5-[4-(trifluoromethoxy)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-76-8 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-77-9 CAPLUS  
CN L-Leucine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-84-8 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-85-9 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-chloro-3-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840533-86-0 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-chloro-3-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-87-1 CAPLUS  
CN D-Leucine, N-[[4-[5-(3-fluoro-4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-88-2 CAPLUS  
CN L-Leucine, N-[[4-[5-(3-fluoro-4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-89-3 CAPLUS  
CN D-Leucine, N-[[4-[5-(1,3-benzodioxol-5-yl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
RN 840533-90-6 CAPLUS  
CN L-Leucine, N-[[4-[5-(1,3-benzodioxol-5-yl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-91-7 CAPLUS  
CN D-Leucine, N-[[4-[5-(2,3-dihydro-5-benzofuranyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-92-8 CAPLUS  
CN L-Leucine, N-[[4-[5-(3,4-dichlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840533-93-9 CAPLUS  
CN D-Leucine, N-[[4-[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-94-0 CAPLUS  
CN D-Leucine, N-[[4-[5-(2,3-dihydro-5-benzofuranyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840533-95-1 CAPLUS  
CN L-Leucine, N-[[4-[5-(3,4-dichlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840533-96-2 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-difluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840533-97-3 CAPLUS  
CN D-Leucine, N-[[4-[5-(3-fluoro-4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840533-98-4 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840533-99-5 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 840534-00-1 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 840534-01-2 CAPLUS  
CN L-Isoleucine, N-[[4-[5-[4-(methylthio)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840534-05-6 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(5-phenyl-3-isoxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840534-06-7 CAPLUS  
CN L-Isoleucine, N-[[4-[5-[4-(trifluoromethoxy)phenyl]-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840534-07-8 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-bromophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840534-08-9 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(3,4-dichlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 840534-09-0 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(3-fluoro-4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840534-10-3 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840534-11-4 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-chlorophenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840534-12-5 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(3,4-difluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 840534-13-6 CAPLUS  
CN D-Valine, 3-methyl-N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840534-15-8 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840534-16-9 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840534-17-0 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 840534-18-1 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-propylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 840534-19-2 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-(trifluoromethyl)phenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 840534-21-6 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-chloro-3-fluorophenyl)-3-isoxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

## 10824057 - Compound Search


L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 840534-22-7 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3-fluoro-4-methoxyphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840534-23-8 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3-fluoro-4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 840534-26-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 840534-27-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-3-isoxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 840534-30-7P 840534-34-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of isoxazole derivs. having sulfonamide moiety as MMP inhibitors)  
RN 840534-30-7 CAPLUS  
CN D-Valine, N-[[4-[3-(4-methylphenyl)-5-isoxazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 840534-34-1 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-methylphenyl)-3-isoxazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L3 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## 10824057 - Compound Search


L3 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:996147 CAPLUS  
DOCUMENT NUMBER: 141:424429  
TITLE: Preparation of substituted carboxylic acids including amino acid derivatives, as inhibitors of protein tyrosine phosphatases for treatment of diabetes, cancer, and related conditions  
INVENTOR(S): Van Zandt, Michael C.; Whitehouse, Darren; Combs, Kerry; Hu, Shaojing  
PATENT ASSIGNEE(S): The Institutes for Pharmaceutical Discovery, LLC, USA  
SOURCE: PCT Int. Appl., 96 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

Check ODF

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099168	A2	20041118	WO 2004-US11371	20040414
WO 2004099168	A3	20050224		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004236173	A1	20041118	AU 2004-236173	20040414
CA 2523714	A1	20041118	CA 2004-2523714	20040414
US 20040266788	A1	20041238	US 2004-823842	20040414
US 7358364	B2	20080425		
EP 1620420	A2	20060816	EP 2004-760538	20040414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004009914	A	20060425	BR 2004-9914	20040414
CN 1812977	A	20060802	CN 2004-80018416	20040414
JP 2006525329	T	20061109	JP 2006-509981	20040414
NO 2005004957	A	20060123	NO 2005-4957	20051025
MX 2005PA11524	A	20060321	MX 2005-PA11524	20051026
IN 2005KN02124	A	20070608	IN 2005-KN2124	20051026
PRIORITY APPLN. INFO.:			US 2003-467057P	P 20030430
			WO 2004-US11371	W 20040414

OTHER SOURCE(S): MARPAT 141:424429  
IT 796034-07-6P, (2S)-2-[[[4-(2-(Dibenzofuran-4-yl)thiazol-4-yl)phenyl]sulfonyl]ethyl]amino]-3-phenylpropionic acid  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(PTP-1B inhibitor; preparation of substituted carboxylic acids as PTP-1B inhibitors for treatment of diabetes, cancer, and related conditions)  
RN 796034-07-6 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(4-dibenzofuranyl)-4-thiazolyl]phenyl]sulfonyl]-N-ethyl- (CA INDEX NAME)

L3 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry.



L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:902361 CAPLUS  
DOCUMENT NUMBER: 141:395802  
TITLE: Preparation of substituted phenylalkanoic acids, including amino acid derivatives  
INVENTOR(S): Van Zandt, Michael C.; Fang, Haiquan; Hu, Shaojing; Whitehouse, Darren  
PATENT ASSIGNEE(S): The Institutes for Pharmaceutical Discovery, LLC, USA  
SOURCE: PCT Int. Appl., 131 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


INSTANT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092146	A2	20041028	WO 2004-US11650	20040414
WO 2004092146	A3	20041229		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AE, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004231106	A1	20041028	AU 2004-231106	20040414
CA 2522080	A1	20041028		20040414
US 20040248937	A1	20041209	US 2004-824057	20040414
EP 1633354	A2	20060315	EP 2004-750170	20040414
EP 1633354	B1	20080123		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004009447	A	20060418	BR 2004-9447	20040414
CN 1794989	A	20060628	CN 2004-80014576	20040414
JP 2006524248	T	20061026	JP 2006-510073	20040414
AT 384526	T	20080215	AT 2004-750170	20040414
NO 2005004769	A	20060517	NO 2005-4769	20051017
IN 2005KN02090	A	20061117	IN 2005-KN2090	20051024
PRIORITY APPLN. INFO.:			US 2003-463102P	P 20030414
			WO 2004-US11650	W 20040414

OTHER SOURCE(S): MARPAT 141:395802  
IT 782483-66-3P 782483-78-7P 782483-80-1P  
782483-81-2P 782483-82-3P 782483-83-4P  
782483-86-7P 782483-93-6P 782483-99-2P  
782484-01-9P 782484-02-0P 782484-05-3P  
782484-06-4P 782484-07-5P 782484-13-3P  
782484-14-4P 782484-15-5P 782484-16-6P  
782484-17-7P 782484-18-8P 782484-26-8P  
782484-27-9P 782484-28-0P 782484-69-9P  
782484-70-2P 782484-72-4P 782484-73-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of substituted phenylalkanoic acids, including amino acid derivs., for treatment of diabetes)  
RN 782483-66-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-5-(4-ethylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


23 APR 2008

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry.




RN 782483-78-7 CAPLUS  
CN L-Phenylalanine, N-[[4-[4,5-dihydro-3-(4-methoxyphenyl)-5-(4-pentylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 782483-80-1 CAPLUS  
CN L-Phenylalanine, N-[[4-[4,5-dihydro-5-(4-pentylphenyl)-3-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 782483-81-2 CAPLUS



## 10824057 - Compound Search


L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN L-Phenylalanine, N-[[4-[3-(4-methoxyphenyl)-5-(4-pentylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 782483-82-3 CAPLUS  
 CN L-Phenylalanine, N-methyl-N-[[4-[5-(4-pentylphenyl)-3-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-1-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 782483-83-4 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(4-butoxyphenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 782483-86-7 CAPLUS  
 CN L-Phenylalanine, N-[[4-[3-(4-methoxyphenyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 782483-93-6 CAPLUS  
 CN L-Phenylalanine, N-methyl-N-[[4-[5-(4-pentylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 RN 782483-99-2 CAPLUS  
 CN L-Phenylalanine, N-[[4-[2-[(4-chlorobenzoyl)amino]-5-(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 782484-01-9 CAPLUS  
 CN L-Phenylalanine, N-[[4-[4-bromo-3-(4-methoxyphenyl)-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-02-0 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(4-bromophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 782484-05-3 CAPLUS  
 CN L-Phenylalanine, N-[[4-[2-[(cyclopentylacetyl)amino]-5-(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 782484-06-4 CAPLUS  
 CN L-Phenylalanine, N-[[4-[2-(4-chlorophenyl)-5-(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-07-5 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-2-(6-methoxy-3-pyridinyl)-4-thiazolyl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


## 10824057 - Compound Search

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry.



RN 782484-13-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-14-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-bromo-3-(4-chlorophenyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 782484-17-7 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-5-(4-pentylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-18-8 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-bromo-3-(4-chlorophenyl)-5-(4-pentylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 782484-15-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-bromo-3-(4-chlorophenyl)-5-(4-ethylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-16-6 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-bromophenyl)-3-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 782484-26-8 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 782484-27-9 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 782484-28-0 CAPLUS  
CN L-Phenylalanine, N-[[4-[2,5-bis(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 782484-69-9 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-bromo-5-(1-dibenzofuranyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-70-2 CAPLUS


L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CN L-Phenylalanine, N-[[4-[5-bromo-2-(1-dibenzofuranyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 782484-72-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(4-chlorophenyl)-5-(6-methoxy-3-pyridinyl)-4-thiazolyl]phenyl]sulfonyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 782484-73-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(1-dibenzofuranyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 782483-64-1P 782483-65-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of substituted phenylalkanoic acids, including amino acid derivs., for treatment of diabetes)

RN 782483-64-1 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-5-(4-ethylphenyl)-4,5-dihydro-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 782483-65-2 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-5-(4-ethylphenyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-N-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



## 10824057 - Compound Search

L3 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:672552 CAPLUS  
 DOCUMENT NUMBER: 141:309423  
 TITLE: Assay of collagenase activity for native triple-helical collagen using capillary gel electrophoresis with laser-induced fluorescence detection  
 AUTHOR(S): Sano, Masatake; Nishino, Ikuko; Ueno, Kyoji; Kamimori, Hiroshi  
 CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi & Co. Ltd., 12-4, Sagisu-5-Chome, Fukushima-ku, Osaka, 553-0002, Japan  
 SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2004), 809(2), 251-256  
 CODEN: JUCBAAI; ISSN: 1570-0232  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 193809-84-6, MMI 166  
 RL: BIOL (Biological study, unclassified); BIOL (Biological study) (evaluation of collagenase inhibitors with collagenase assay using capillary gel electrophoresis with laser-induced fluorescence detection)  
 RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:591055 CAPLUS  
 DOCUMENT NUMBER: 142:126494  
 TITLE: Flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm  
 AUTHOR(S): Dadraaz, Orkideh Ghorban; Sobhani, Armin Madadkar; Shafiee, Abbas; Mahmoudian, Massoud  
 CORPORATE SOURCE: Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Research Centre, Tehran University of Medical Sciences, Tehran, Iran  
 SOURCE: Daru, Journal of Faculty of Pharmacy, Tehran University of Medical Sciences (2004), 12(1), 1-10  
 CODEN: DJTSFE; ISSN: 1565-0115  
 PUBLISHER: Tehran University of Medical Sciences, Faculty of Pharmacy  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 242816-44-0, (S)-DPS  
 RL: PKT (Pharmacokinetics); BIOL (Biological study) (flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm showed that carboxylate form of (R)-DPS ligand showed good docking quality)  
 RN 242816-44-0 CAPLUS  
 CN D-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



IT 191474-92-7, (S)-DPS  
 RL: PKT (Pharmacokinetics); BIOL (Biological study) (flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm showed that carboxylate form of (S)-DPS ligand showed excellent docking quality)  
 RN 191474-92-7 CAPLUS  
 CN L-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:153564 CAPLUS  
 DOCUMENT NUMBER: 140:375101  
 TITLE: New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors  
 AUTHOR(S): Delbecq, Frederic; Cordonnier, Guy; Pommery, Nicole; Barbry, Didier; Henichart, Jean-Pierre  
 CORPORATE SOURCE: Groupe de Recherche pour l'Inhibition de la Prolifération Cellulaire UPRES EA 2692, Equipe de Chimie Organique, Université des Sciences et Technologies de Lille, Villeneuve d'Ascq, F-59655, Fr.  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1119-1121  
 CODEN: BMCLEB; ISSN: 0960-894X  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 140:375101  
 IT 408503-64-0P 685508-84-3P 685508-86-5P  
 685508-88-7P, N-[[4-[5-(4-Methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-DL-glutamic acid 1-methyl ester  
 685508-91-2P 685508-92-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of (oxazolyl)benzenesulfonamides and (thiazolyl)benzenesulfonamides and study of their activity as matrix metalloproteinase inhibitors)  
 RN 408503-64-0 CAPLUS  
 CN L-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 685508-84-3 CAPLUS  
 CN L-Valine, N-[[4-[4-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 685508-86-5 CAPLUS  
CN L-Glutamic acid, N-[[4-[4-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 685508-88-7 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 685508-91-2 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 685508-77-4 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-, methyl  
ester (CA INDEX NAME)

Absolute stereochemistry.



RN 685508-78-5 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-,  
dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685508-80-9 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-, methyl  
ester (CA INDEX NAME)

Absolute stereochemistry.


23 APR 2008

L3 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 685508-92-3 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



IT 685508-72-9P 685508-77-4P 685508-78-5P  
685508-80-9P 685508-82-1P 862902-46-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or Reagent)  
(preparation of (oxazolyl)benzenesulfonamides and  
(thiazolyl)benzenesulfonamides and study of their activity as matrix  
metalloproteinase inhibitors)  
RN 685508-82-9 CAPLUS  
CN L-Valine, N-[[4-[4-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-, methyl  
ester (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 685508-82-1 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-,  
dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862902-46-3 CAPLUS  
CN L-Glutamic acid, N-[[4-[4-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-,  
dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## 10824057 - Compound Search


L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
ACCESSION NUMBER: 2003:77577 CAPLUS  
DOCUMENT NUMBER: 139:286336  
TITLE: Medicinal composition containing inhibitor of decomposition of extracellular matrix of cartilage  
INVENTOR(S): Gemba, Takefumi; Okamoto, Hiroyuki; Mitanabe, Fumihiko  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 101 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080042	A1	2003-10-02	WO 2003-JP3673	2003-03-26
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RW, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003221160	A1	2003-10-08	AU 2003-221160	2003-03-26
EP 1491190	A1	2004-12-29	EP 2003-712957	2003-03-26
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050227994	A1	2005-10-13	US 2004-508530	2004-09-21
PRIORITY APPLN. INFO.: JP 2002-87330 A 2002-03-27 WO 2003-JP3673 W 2003-03-26				

OTHER SOURCE(S): MARPAT 139:286336  
IT 193810-02-5P 261759-17-5P 301835-46-1P  
301835-73-4P 301835-79-0P 370597-80-1P  
370597-93-6P 372105-93-6P 372106-03-1P  
372106-08-6P 372106-11-1P 372160-38-8P  
372160-39-9P 372160-43-5P 372160-52-6P  
408503-22-0P 408503-36-6P 408503-54-8P  
408503-75-3P 408503-88-8P 408503-89-9P  
408503-91-3P 408503-92-4P 408504-02-9P  
408504-03-0P 408504-08-5P 408504-09-6P  
519008-07-2P 519008-34-5P 519008-35-6P  
519008-36-7P 519008-45-8P 519008-49-2P  
519008-51-6P 519008-52-7P 519008-54-9P  
519008-55-0P 519008-58-3P 607718-98-9P  
607719-00-6P 607719-02-8P 607719-03-9P  
607719-06-2P 607719-07-3P 607719-08-4P  
607719-09-5P 607719-10-8P 607719-11-9P  
607719-13-1P 607719-15-3P 607719-16-4P  
607719-17-5P 607719-21-1P 607719-47-1P  
607719-48-2P 607719-49-3P 607719-50-6P  
607719-51-7P 607719-52-8P 607719-53-9P  
607719-54-0P 607719-55-1P 607719-56-2P  
607719-57-3P 607719-60-8P 607719-61-9P  
607719-62-0P 607719-64-2P 607719-65-3P  
607719-66-4P 607719-67-5P 607719-68-6P


L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
607719-69-7P 607719-70-0P 607719-71-1P  
607719-97-1P 607719-99-3P 607720-01-4P  
607720-02-5P 607720-03-6P 607720-04-7P  
607720-10-5P 607720-12-7P 607720-14-9P  
607720-16-1P 607720-29-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOC (Biological study); PREP (Preparation); USES (Uses)  
(medicinal compn. contg. inhibitor of decompn. of extracellular matrix of cartilage and prepn. of said inhibitor)  
RN 193810-02-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 261759-17-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 301835-46-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-73-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-79-0 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-80-1 CAPLUS  
CN D-Alanine, N-[[4-[2-(6-methoxy-2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 370597-93-6 CAPLUS  
CN D-Methionine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-93-6 CAPLUS  
CN D-Valine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-03-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-08-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-11-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372160-38-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372160-39-9 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372160-43-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372160-52-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(2-naphthalenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-22-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-36-6 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-54-8 CAPLUS  
CN L-Alanine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-75-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-88-8 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-89-9 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-91-3 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


## 10824057 - Compound Search

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry.




RN 408503-92-4 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 408504-02-9 CAPLUS  
CN D-Methionine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-34-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 519008-35-6 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408504-03-0 CAPLUS  
CN D-Methionine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 408504-08-5 CAPLUS  
CN D-Alanine, N-[[4-[5-(2-naphthalenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 408504-09-6 CAPLUS  
CN L-Alanine, N-[[4-[5-(2-naphthalenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 519008-07-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 519008-36-7 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 519008-45-8 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 519008-49-2 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-51-6 CAPLUS  
CN D-Alanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 519008-52-7 CAPLUS  
CN D-Valine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-54-9 CAPLUS  
CN D-Methionine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-55-0 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 519008-58-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 607718-98-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thienyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607719-00-6 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(5-phenyl-2-thiazolyl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 607719-02-8 CAPLUS  
CN D-Glutamic acid, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 607719-03-9 CAPLUS  
CN L-Valine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607719-06-2 CAPLUS  
CN D-Glutamic acid, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 607719-07-3 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(methylthio)phenyl]-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 607719-08-4 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(methylthio)phenyl]-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


# 10824057 - Compound Search

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry.




RN 607719-09-5 CAPLUS  
CN L-Alanine, N-[[4-[5-[4-(methylthio)phenyl]-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-10-8 CAPLUS  
CN D-Glutamic acid, N-[[4-[5-[4-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607719-17-5 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-[4-(1-methylethyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-21-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-[4-(methylthio)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-47-1 CAPLUS  
CN L-Alanine, N-[[4-[5-[4-(4-methoxyphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-48-2 CAPLUS

23 APR 2008

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 607719-11-9 CAPLUS  
CN D-Alanine, N-[[4-[5-[4-(1-methylethyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-13-1 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(1-methylethyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-15-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-[4-(1-methylethyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-16-4 CAPLUS  
CN D-Methionine, N-[[4-[5-[4-(1-methylethyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CN D-Methionine, N-[[4-[5-[4-(methylthio)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-49-3 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(methylthio)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-50-6 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(4-ethoxyphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-51-7 CAPLUS  
CN D-Methionine, N-[[4-[5-[4-(4-methoxyphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




## 10824057 - Compound Search

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 607719-52-8 CAPLUS  
CN L-Tryptophan, N-[[4-[5-[4-(1-pyrrolidinyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-53-9 CAPLUS  
CN Acetic acid, bromo[[4-[5-(4-bromophenyl)-2-thienyl]phenyl]sulfonylamino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-54-0 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(4-methoxyphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607719-55-1 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 607719-61-9 CAPLUS  
CN D-Alanine, N-[[4-[5-[4-(1H-pyrrol-1-yl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607719-62-0 CAPLUS  
CN D-Leucine, N-[[4-[5-[4-(1-piperidinyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607719-56-2 CAPLUS  
CN D-Tryptophan, N-[[4-[5-[4-(dimethylamino)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-57-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-[4-(methylamino)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607719-60-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-[4-(1H-pyrrol-1-yl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607719-64-2 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(1-pyrrolidinyl)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-65-3 CAPLUS  
CN L-Tryptophan, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-66-4 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

# 10824057 - Compound Search


L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 607719-67-5 CAPLUS  
CN L-Valine, N-[[4-[5-[4-(methylamino)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-68-6 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-[4-(methylamino)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607719-69-7 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-[4-(methylthio)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 607719-70-0 CAPLUS  
CN L-Methionine, N-[[4-[5-(4-acetylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607719-71 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethenylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607719-97-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-[2-(acetylamino)ethyl]phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607719-99-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-(2-aminoethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607720-01-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-[2-[(methylsulfonyl)oxy]ethyl]phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607720-02-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-butylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 607720-03-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-[4-(methylthio)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607720-04-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-butoxyphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607720-10-5 CAPLUS  
CN D-Valine, N-[[4-[5-(4-butylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607720-12-7 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 607720-14-9 CAPLUS  
CN D-Methionine, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607720-16-1 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(methylthio)phenyl]-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607720-29-6 CAPLUS  
CN D-Alanine, N-methyl-N-[[4-[2-(4-methylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:77576 CAPLUS  
DOCUMENT NUMBER: 139:281273  
TITLE: N-Sulfonylamino acid derivatives as remedies for arthritis deformans  
INVENTOR(S): Gemba, Takefumi; Watanabe, Fumihiko  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080041	A1	20031002	WO 2003-JP3672	20030326
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UM, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GB, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003221158	A1	20031008	AU 2003-221158	20030326
PRIORITY APPLN. INFO.:			JP 2002-87318	A 20020327
			WO 2003-JP3672	W 20030326

IT 301835-46-1P 408503-61-7P 408503-63-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-sulfonylamino acid derivs. as remedies for arthritis deformans)  
RN 301835-46-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 408503-61-7 CAPLUS  
CN D-Valine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 604808-90-4P 607720-48-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(medicinal composition containing inhibitor of decomposition of extracellular matrix of cartilage and preparation of said inhibitor)


RN 604808-90-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 607720-48-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thienyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 408503-63-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 604808-90-4P 604808-92-6P 604808-94-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-sulfonylamino acid derivs. as remedies for arthritis deformans)

RN 604808-90-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 604808-92-6 CAPLUS  
CN D-Valine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

23 APR 2008

# 10824057 - Compound Search


L3 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 ester (CA INDEX NAME)

Absolute stereochemistry.



RN 604808-94-8 CAPLUS  
 CN D-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:757689 CAPLUS  
 DOCUMENT NUMBER: 139:276755  
 TITLE: Preparation of epothilone derivatives for therapeutic use as anticancer agents  
 INVENTOR(S): Requeiro-Ren, Alicia; Kim, Soong-Hoon  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078411	A1	20030925	WO 2003-US7584	20030311
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MG, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003218110	A1	20030929	AU 2003-218110	20030311
US 20030191089	A1	20031009	US 2003-386072	20030311
US 6719540	B2	20040413		
EP 1483251	A1	20041208	EP 2003-714096	20030311
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-363441P	P 20020312
			WO 2003-US7584	W 20030311

OTHER SOURCE(S): MARPAT 139:276755  
 IT 193809-84-6, MMI 166  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical composition containing epothilone derivs and; preparation of epothilone derivs. for therapeutic use as anticancer agents)  
 RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




L3 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:757513 CAPLUS  
 DOCUMENT NUMBER: 139:276754  
 TITLE: Preparation of C12-cyano epothilone derivatives with antitumor activity  
 INVENTOR(S): Vite, Gregory D.; Requeiro-Ren, Alicia  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077903	A1	20030925	WO 2003-US7576	20030311
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MG, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003218107	A1	20030929	AU 2003-218107	20030311
US 20030186965	A1	20031002	US 2003-386059	20030311
US 7211593	B2	20070501		
PRIORITY APPLN. INFO.:			US 2002-363703P	P 20020312
			WO 2003-US7576	W 20030311

OTHER SOURCE(S): MARPAT 139:276754  
 IT 193809-84-6, MMI 166  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (therapeutic agent for use with C12-cyano epothilone derivs.)  
 RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


## 10824057 - Compound Search

L3 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:696720 CAPLUS  
DOCUMENT NUMBER: 139:219348  
TITLE: Solid preparations with improved absorbability of  
hardly water-soluble drugs  
INVENTOR(S): Hayashi, Takashi; Takakura, Asako  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072085	A1	20030904	WO 2003-JP1965	20030224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003211267	A1	20030909	AU 2003-211267	20030224
PRIORITY APPLN. INFO.:			JP 2002-52017	A 20020227
			WO 2003-JP1965	W 20030224

OTHER SOURCE(S): MARPAT 139:219348  
IT 372106-05-3  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(solid prepsns. with improved absorbability of hardly water-soluble drugs)  
RN 372106-05-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:643131 CAPLUS  
DOCUMENT NUMBER: 140:419732  
TITLE: Docking studies of matrix metalloproteinase  
inhibitors: inc parameter optimization to improve the  
binding free energy prediction  
AUTHOR(S): Hu, Xing-Shelver, William H.  
CORPORATE SOURCE: Department of Pharmaceutical Science, North Dakota  
State University, Fargo, ND, 58105, USA  
SOURCE: Journal of Molecular Graphics & Modelling (2003),  
20(2), 115-126  
CODEN: JMGMPF; ISSN: 1093-3263  
PUBLISHER: Elsevier Science Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 191474-92-7 242816-44-0


RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
(Biological study)  
(docking studies of matrix metalloproteinase inhibitors)  
RN 191474-92-7 CAPLUS  
CN L-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 242816-44-0 CAPLUS  
CN D-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:335071 CAPLUS  
DOCUMENT NUMBER: 138:353829  
TITLE: Preparation of sulfonamide derivatives as MMP  
inhibitors for treatment of chronic obstructive lung  
disease  
INVENTOR(S): Watanabe, Fumitiko; Tamura, Yoshinori  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 102 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035610	A1	20030501	WO 2002-JP11046	20021024
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002344572	A1	20030506	AU 2002-344572	20021024
PRIORITY APPLN. INFO.:			JP 2001-330048	A 20011026
			WO 2002-JP11046	W 20021024

OTHER SOURCE(S): MARPAT 138:353829  
IT 301835-79-0P 301835-80-3P 301835-81-4P  
519007-83-1P 519007-84-2P 519007-85-3P  
519007-86-4P 519007-87-5P 519007-88-6P  
519007-89-7P 519007-90-0P 519007-91-1P  
519007-92-2P 519007-93-3P 519007-94-4P  
519007-95-5P 519007-96-6P 519007-98-8P  
519008-00-5P 519008-03-8P 519008-05-0P  
519008-07-2P 519008-09-4P 519008-11-8P  
519008-13-0P 519008-15-2P 519008-17-4P  
519008-19-6P 519008-21-0P 519008-23-2P  
519008-25-4P 519008-27-6P 519008-29-8P  
519008-31-2P 519008-33-4P 519008-34-5P  
519008-35-6P 519008-36-7P 519008-37-8P  
519008-38-9P 519008-39-0P 519008-40-3P  
519008-41-4P 519008-42-5P 519008-43-6P  
519008-44-7P 519008-45-8P 519008-46-9P  
519008-47-0P 519008-48-1P 519008-49-2P  
519008-50-5P 519008-51-6P 519008-52-7P  
519008-53-8P 519008-54-9P 519008-55-0P  
519008-56-1P 519008-57-2P 519008-58-3P  
519008-59-4P 519008-60-7P 519008-61-8P  
519008-62-9P 519008-63-0P 519008-64-1P  
519008-65-2P 519008-66-3P 519008-67-4P  
519008-68-5P 519008-69-6P 519008-70-9P  
519008-71-0P 519008-72-1P 519008-73-2P  
519008-74-3P 519008-75-4P 519008-76-5P  
519008-77-6P 519008-78-7P 519008-79-8P  
519008-80-1P 519008-81-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

## 10824057 - Compound Search


L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 (MMP inhibitor; prepn. of benzenesulfonamide derivs. as MMP inhibitors  
 for treatment of chronic obstructive lung disease)  
 RN 301835-79-0 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-80-3 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-81-4 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519007-83-1 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519007-84-2 CAPLUS  
 CN D-Alanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519007-85-3 CAPLUS  
 CN D-Valine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519007-86-4 CAPLUS  
 CN D-Leucine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519007-87-5 CAPLUS  
 CN D-Methionine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519007-88-6 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519007-89-7 CAPLUS  
 CN D-Alanine, N-[[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 519007-90-0 CAPLUS  
 CN D-Valine, N-[[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519007-91-1 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519007-92-2 CAPLUS  
 CN D-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519007-93-3 CAPLUS  
 CN D-Valine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519007-94-4 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519007-95-5 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519007-96-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-difluorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519007-98-8 CAPLUS  
CN D-Valine, N-[[4-[5-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519008-00-5 CAPLUS  
CN D-Valine, N-[[4-[5-(3-fluoro-4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-03-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-05-0 CAPLUS  
CN D-Valine, N-[[4-[3-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-07-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-09-4 CAPLUS  
CN Alanine, N-[[4-[3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)




RN 519008-11-8 CAPLUS  
CN D-Valine, N-[[4-[3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-13-0 CAPLUS  
CN D-Valine, N-[[4-[3-(3-bromo-4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519008-15-2 CAPLUS  
CN D-Valine, N-[[4-[3-(3-fluoro-4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-17-4 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-19-6 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-21-0 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-23-2 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-difluorophenyl)-1,3,4-thiadiazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-25-4 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-dichlorophenyl)-1,3,4-thiadiazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-27-6 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-29-8 CAPLUS  
CN L-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-31-2 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-33-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-34-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-35-6 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-36-7 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-dichlorophenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-37-8 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-38-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-39-0 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-40-3 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 519008-41-4 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-42-5 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-dimethoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-43-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-44-7 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-45-8 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-46-9 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-47-0 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-48-1 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-49-2 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(3,4-difluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-50-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519008-51-6 CAPLUS  
CN D-Alanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-52-7 CAPLUS  
CN D-Valine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-56-1 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519008-57-2 CAPLUS  
CN L-Alanine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-58-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


23 APR 2008

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-53-8 CAPLUS  
CN D-Leucine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519008-54-9 CAPLUS  
CN D-Methionine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 519008-55-0 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-59-4 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 519008-60-7 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-61-8 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-62-9 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-dichlorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-63-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-64-1 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-65-2 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-66-3 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-67-4 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 519008-68-5 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-69-6 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(3,4-difluorophenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-70-9 CAPLUS  
CN D-Alanine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-71-0 CAPLUS  
CN D-Valine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-72-1 CAPLUS  
CN D-Leucine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-73-2 CAPLUS  
CN D-Methionine, N-[[4-[5-(3,4-dimethoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-74-3 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(3,4-dimethoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-75-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 519008-76-5 CAPLUS  
CN D-Alanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 519008-77-6 CAPLUS  
CN D-Valine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 519008-78-7 CAPLUS  
CN D-Leucine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 519008-79-8 CAPLUS  
CN D-Methionine, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 519008-80-1 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(1,3-benzodioxol-5-yl)-2-oxazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 519008-81-2 CAPLUS  
CN D-Valine, N-[[4-[2-(3,4-dichlorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:301062 CAPLUS  
DOCUMENT NUMBER: 138:321274  
TITLE: Preparation of diphenyloxazoles as fluorescence probes  
INVENTOR(S): Calver, Theodore E., Jr.; Rinker, James M.  
PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 109 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031419	A1	20030417	WO 2002-US31910	20021007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IL, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462000	A1	20030417	CA 2002-2462000	20021007
AU 2002334874	A1	20030422	AU 2002-334874	20021007
AU 2002334874	B2	20070906		
EP 1442027	A1	20040804	EP 2002-800927	20021007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005531490	T	20051020	JP 2003-534402	20021007
US 20030105111	A1	20030605	US 2002-267118	20021009
US 6815445	B2	20041109		
MX 2004PA03451	A	20050217	MX 2004-PA3451	20040412
US 20040248301	A1	20041209	US 2004-891259	20040714
US 7078406	B2	20060718		

PRIORITY APPL. INFO.: US 2001-327307P P 20011009  
WO 2002-US31910 W 20021007  
US 2002-267118 A3 20021009

OTHER SOURCE(S): MARPAT 138:321274  
IT 511535-91-4P, (S)-2-[[[4-[5-(4-dimethylaminophenyl)oxazol-2-yl]phenyl]sulfonyl]amino]succinic acid  
Rl: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fluorescence probe; preparation of diphenyloxazoles as fluorescence probes)  
RN 511535-91-4 CAPLUS  
CN L-Aspartic acid, N-[[4-[5-[4-(dimethylamino)phenyl]-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




# 10824057 - Compound Search

L3 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:116516 CAPLUS  
 DOCUMENT NUMBER: 139:242328  
 TITLE: New sulfonamide and sulfonic ester porphyrins as sensitizers for photodynamic therapy  
 AUTHOR(S): Sobral, Abilio J. F. N.; Eleouet, Sabine; Rousset, Nathalie; Gonsalves, Antonio M. d'A. Rocha; Le Meur, Olivier; Bourre, Ludovic; Patrice, Thierry  
 CORPORATE SOURCE: Departamento de Quimica, FCTUC Universidade de Coimbra, Coimbra, 3004-535, Port.  
 SOURCE: Journal of Porphyrins and Phthalocyanines (2002), 6(7 & 8), 456-462  
 CODEN: JPPHFZ ISSN: 1088-4246  
 PUBLISHER: Society of Porphyrins & Phthalocyanines  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 596102-93-1P 596102-93-3P  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (sulfonamide and sulfonic ester porphyrins as sensitizers for photodynamic therapy)  
 RN 596102-93-1 CAPLUS  
 CN L-Phenylalanine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetraltetrakis(4,1-phenylenesulfonyl)]tetrakis-, tetramethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L3 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A




RN 596102-95-3 CAPLUS  
 CN L-Methionine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetraltetrakis(4,1-phenylenesulfonyl)]tetrakis-, tetramethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


PAGE 1-A




PAGE 1-B

L3 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



## 10824057 - Compound Search

L3 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:87839 CAPLUS  
DOCUMENT NUMBER: 139:190773  
TITLE: Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents  
AUTHOR(S): Hojo, Kanji; Maekawa, Hideo; Sawada, Takuko Yamada; Maekawa, Ryuji; Yoshioka, Takayuki  
CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi + Co. Ltd, Fukushima-ku, Osaka, Japan  
SOURCE: Anticancer Research (2002), 22(6A), 3253-3259  
CODEN: ANTRD4; ISSN: 0250-7005  
PUBLISHER: International Institute of Anticancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI 166  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(matrix metalloproteinase inhibitor MMI-166 augmentation of B16-BL6 melanoma growth inhibition by combined treatment with paclitaxel and carboplatin)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:20428 CAPLUS  
DOCUMENT NUMBER: 138:331066  
TITLE: The role of MMPs in tumor invasion, metastasis and angiogenesis  
AUTHOR(S): Maekawa, Hyuji  
CORPORATE SOURCE: Research Lab. for Drug Discovery, Shionogi Seiyaku Co., Ltd., Fukushima-ku, Osaka, 553-0002, Japan  
SOURCE: Kan, Tan, Sui (2003), 45(4), 503-510  
CODEN: KTSUDO; ISSN: 0389-4991  
PUBLISHER: Aku Media  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: Japanese  
IT 193809-84-6, MMI-166  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(matrix metalloproteinase inhibitor effects on tumor invasion, metastasis and angiogenesis)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:722320 CAPLUS  
DOCUMENT NUMBER: 139:46491  
TITLE: Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11  
AUTHOR(S): Maekawa, Hideo; Hojo, Kanji; Tanaka, Hidekazu; Sawada, Takuko Yamada; Maekawa, Ryuji; Yoshioka, Takayuki  
CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi + Co Ltd, Fukushima-ku, Osaka, Japan  
SOURCE: Clinical & Experimental Metastasis (2002), 19(6), 519-526  
CODEN: CEXMD2; ISSN: 0262-0898  
PUBLISHER: Kluwer Academic Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI 166  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(augmented anti-metastatic efficacy of matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:275975 CAPLUS  
DOCUMENT NUMBER: 136:294823  
TITLE: Preparation of thiazole or oxazole derivatives as matrix metalloprotease inhibitors  
INVENTOR(S): Watanabe, Fumihiko; Tamura, Yoshinori  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 67 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028844	A1	20020411	WO 2001-JP8507	20010928
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
FW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001092285	A	20020415	AU 2001-92285	20010928
CA 2423885	A1	20030327	CA 2001-2423885	20010928
EP 1331224	A1	20030730	EP 2001-972561	20010928
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20040024029	A1	20040205	US 2003-381280	20030324
US 6949566	B2	20050927		
PRIORITY APPLN. INFO.:			JP 2000-298199	A 20000929
			WO 2001-JP8507	W 20010928

OTHER SOURCE(S): MARPAT 136:294823

IT 408503-08-2P 408503-09-3P 408503-10-6P  
408503-11-7P 408503-12-8P 408503-13-9P  
408503-14-0P 408503-15-1P 408503-16-2P  
408503-17-3P 408503-18-4P 408503-19-5P  
408503-20-8P 408503-21-9P 408503-22-0P  
408503-23-1P 408503-24-2P 408503-25-3P  
408503-26-4P 408503-27-5P 408503-28-6P  
408503-29-7P 408503-30-0P 408503-31-1P  
408503-32-2P 408503-33-3P 408503-34-4P  
408503-35-5P 408503-36-6P 408503-37-7P  
408503-38-8P 408503-39-9P 408503-40-2P  
408503-41-3P 408503-42-4P 408503-43-5P  
408503-45-7P 408503-46-8P 408503-47-9P  
408503-48-0P 408503-49-1P 408503-50-4P  
408503-51-5P 408503-53-7P 408503-54-8P  
408503-55-9P 408503-56-0P 408503-57-1P  
408503-58-2P 408503-59-3P 408503-60-6P  
408503-61-7P 408503-62-8P 408503-63-9P  
408503-64-0P 408503-65-1P 408503-66-2P  
408503-67-3P 408503-68-4P 408503-69-5P  
408503-70-8P 408503-71-9P 408503-72-0P  
408503-73-1P 408503-74-2P 408503-75-3P  
408503-76-4P 408503-77-5P 408503-78-6P  
408503-79-7P 408503-80-0P 408503-81-1P  
408503-82-2P 408503-83-3P 408503-84-4P  
408503-85-5P 408503-86-6P 408503-87-7P  
408503-88-8P 408503-89-9P 408503-90-2P

## 10824057 - Compound Search

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

408503-91-3P 408503-92-4P 408503-93-5P  
408503-94-6P 408503-95-7P 408503-96-8P  
408503-97-9P 408503-98-0P 408503-99-1P  
408504-00-7P 408504-01-8P 408504-02-9P  
408504-03-0P 408504-04-1P 408504-05-2P  
408504-06-3P 408504-08-5P 408504-09-6P  
408523-99-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of thiazole or oxazole derivs. as matrix metalloprotease inhibitors)

RN 408503-08-2 CAPLUS

CN D-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 408503-09-3 CAPLUS

CN D-Alanine, N-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-10-6 CAPLUS

CN L-Alanine, N-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 408503-11-7 CAPLUS

CN D-Alanine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-12-8 CAPLUS

CN L-Alanine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-13-9 CAPLUS

CN D-Alanine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



RN 408503-14-0 CAPLUS

CN L-Alanine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-15-1 CAPLUS

CN D-Alanine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-16-2 CAPLUS

CN L-Alanine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



RN 408503-17-3 CAPLUS

CN D-Alanine, N-[[4-[5-(4-bromophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-18-4 CAPLUS

CN L-Alanine, N-[[4-[5-(4-bromophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-19-5 CAPLUS

23 APR 2008

## 10824057 - Compound Search


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN D-Phenylalanine, N-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-20-8 CAPLUS  
 CN L-Phenylalanine, N-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-21-9 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-22-0 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]-


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-23-1 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-24-2 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-25-3 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-26-4 CAPLUS  
 CN D-Phenylalanine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-27-5 CAPLUS  
 CN L-Phenylalanine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 Absolute stereochemistry.




RN 408503-28-6 CAPLUS  
 CN D-Valine, N-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-29-7 CAPLUS  
 CN L-Valine, N-[[4-(5-phenyl-2-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-30-0 CAPLUS  
 CN D-Valine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-31-1 CAPLUS  
CN L-Valine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-32-2 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-36-6 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-37-7 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-38-8 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-33-3 CAPLUS  
CN L-Valine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-34-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-bromophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-35-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 408503-39-9 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-40-2 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-bromophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-41-3 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

# 10824057 - Compound Search


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 408503-42-4 CAPLUS  
CN D-Methionine, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-43-5 CAPLUS  
CN D-Methionine, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 408503-45-7 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-46-8 CAPLUS  
CN L-Aspartic acid, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-47-9 CAPLUS  
CN L-Aspartic acid, N-[[4-[5-(4-fluorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-48-0 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-methoxyphenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-49-1 CAPLUS  
CN L-Alanine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-50-4 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-51-5 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-53-7 CAPLUS  
CN D-Alanine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-54-8 CAPLUS  
CN L-Alanine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

## 10824057 - Compound Search


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 408503-55-9 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-56-0 CAPLUS  
CN D-Valine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-57-1 CAPLUS  
CN L-Valine, N-[[4-[5-(2-naphthalenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-58-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 408503-59-3 CAPLUS  
CN D-Valine, N-[[4-(5-phenyl-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-60-6 CAPLUS  
CN L-Valine, N-[[4-(5-phenyl-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-61-7 CAPLUS  
CN D-Valine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-62-8 CAPLUS  
CN L-Valine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-63-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-64-0 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-65-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-66-2 CAPLUS  
CN L-Valine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

## 10824057 - Compound Search


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 408503-67-3 CAPLUS  
CN D-Valine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-68-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-69-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-72-0 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-73-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-74-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




23 APR 2008

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


NAME)

Absolute stereochemistry.




RN 408503-70-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-71-9 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-75-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-76-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-77-5 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-78-6 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl)sulfonyl]- (CA INDEX NAME)



## 10824057 - Compound Search


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 408503-79-7 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-80-0 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-81-1 CAPLUS

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


CN D-Alanine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-82-2 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-83-3 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-84-4 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-85-5 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-86-6 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 408503-87-7 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-88-8 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-89-9 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

23 APR 2008

## 10824057 - Compound Search


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 408503-90-2 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408503-91-3 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408503-92-4 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-93-5 CAPLUS  
CN L-Isoleucine, N-[[4-[5-(4-bromophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-94-6 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-95-7 CAPLUS  
CN L-Aspartic acid, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-96-8 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 408503-97-9 CAPLUS  
CN L-Aspartic acid, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408503-98-0 CAPLUS  
CN L-Aspartic acid, N-[[4-[5-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408503-99-1 CAPLUS  
CN L-Glutamic acid, N-[[4-[5-(4-chlorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408504-00-7 CAPLUS  
CN D-Methionine, N-[[4-[(5-phenyl-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408504-01-8 CAPLUS  
CN D-Methionine, N-[[4-[(5-(4-chlorophenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 408504-02-9 CAPLUS  
CN D-Methionine, N-[[4-[(5-(4-methoxyphenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408504-05-2 CAPLUS  
CN L-Methionine, N-[[4-[(5-(4-bromophenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408504-06-3 CAPLUS  
CN D-Histidine, N-[[4-[(5-(4-chlorophenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408504-08-5 CAPLUS  
CN D-Alanine, N-[[4-[(5-(2-naphthalenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 408504-03-0 CAPLUS  
CN D-Methionine, N-[[4-[(5-(4-bromophenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 408504-04-1 CAPLUS  
CN D-Methionine, N-[[4-[(5-(4-fluorophenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408504-09-6 CAPLUS  
CN L-Alanine, N-[[4-[(5-(2-naphthalenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 408523-99-9 CAPLUS  
CN D-Glutamic acid, N-[[4-[(5-(4-chlorophenyl)-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 408504-13-2P 408504-15-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of thiazole or oxazole derivs. as matrix metalloprotease inhibitors)  
RN 408504-13-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[(5-(2-naphthalenyl)-2-thiazolyl)phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


## 10824057 - Compound Search

L3 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 408504-15-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-methoxyphenyl)-2-thiazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L3 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:268574 CAPLUS  
DOCUMENT NUMBER: 136:304108  
TITLE: Sulfonilaminosuccinimides and matrix metalloprotease inhibitors containing them  
INVENTOR(S): Watanabe, Fumihiko; Araki, Yoshitake; Fujii, Yasuhiko  
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002105073	A	20020410	JP 2000-293425	20000927

PRIORITY APPLN. INFO.:  
OTHER SOURCE(S):  
IT 408503-45-7P 409055-05-8P  
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of sulfonilaminosuccinimides as matrix metalloprotease inhibitors)  
RN 408503-45-7 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 409059-05-8 CAPLUS  
CN D-Aspartic acid, N-[[4-[5-(4-chlorophenyl)-2-oxazolyl]phenyl]sulfonyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:242596 CAPLUS  
DOCUMENT NUMBER: 138:130  
TITLE: Anti-invasive Effect of MMI-166, a New Selective Matrix Metalloproteinase Inhibitor, in Cervical Carcinoma Cell Lines  
AUTHOR(S): Iwasaki, Masahiro; Nishikawa, Akira; Fujimoto, Takashi; Akutagawa, Noriyuki; Tanase, Kengo; Endo, Toshiaki; Yoshida, Koichi; Maekawa, Ryuji; Yoshioka, Takayuki; Kudo, Ryuichi  
CORPORATE SOURCE: Department of Obstetrics and Gynecology, Sapporo Medical University, Sapporo, 060-8543, Japan  
SOURCE: Gynecologic Oncology (2002), 85(1), 103-107  
CODEN: GYNODJ; ISSN: 0090-8258  
PUBLISHER: Elsevier Science  
DOCUMENT TYPE: Journal Article  
LANGUAGE: English  
IT 193809-84-6, MMI 166  
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MMI 166; Anti-invasive effect of selective matrix metalloproteinase inhibitor MMI-166 in cervical carcinoma cell lines)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## 10824057 - Compound Search

L3 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:225915 CAPLUS  
DOCUMENT NUMBER: 137:11905  
TITLE: Comparative docking study and the design of potentially selective MMP inhibitors  
AUTHOR(S): Hanessian, Stephen; Moitessier, Nicolas; Therrien, Eric  
CORPORATE SOURCE: Department of Chemistry, Universite de Montreal, Montreal, QC, H3C 3J7, Can.  
SOURCE: Journal of Computer-Aided Molecular Design (2001), 15(10), 873-881  
CODEN: JCADEQ; ISSN: 0920-654X  
PUBLISHER: Kluwer Academic Publishers  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 191474-92-7  
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)  
(comparative docking study and the design of potentially selective MMP inhibitors)  
RN 191474-92-7 CAPLUS  
CN L-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:151291 CAPLUS  
DOCUMENT NUMBER: 137:304345  
TITLE: Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck  
AUTHOR(S): Katori, Hideaki; Baba, Yuh; Imagawa, Yukari; Nishimura, Goshi; Kagesato, Yuumi; Takagi, Eri; Ishii, Akiko; Yanoma, Shunsuke; Maekawa, Ryuji; Yoshida, Takayuki; Nagashima, Yoji; Kato, Yasumasa; Tsukuda, Mamoru  
CORPORATE SOURCE: Department of Otolaryngology, Yokohama City University School of Medicine, Kanazawa-ku, Yokohama, 236-0004, Japan  
SOURCE: Cancer Letters (Shannon, Ireland) (2002), 178(2), 151-159  
CODEN: CALEDQ; ISSN: 0304-3835  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI 166  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(MMI 166; effect of MMI-166, selective matrix metalloproteinase inhibitor, on tumor angiogenesis and apoptosis in squamous cell carcinoma cell lines of head and neck)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:884078 CAPLUS  
DOCUMENT NUMBER: 136:334870  
TITLE: Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166  
AUTHOR(S): Oba, Kouji; Konno, Hiroyuki; Tanaka, Tatsuo; Baba, Megumi; Kamiya, Kinji; Ohta, Manabu; Kaneko, Takeshi; Shouji, Tsuyoshi; Igarashi, Akira; Nakamura, Satoshi  
CORPORATE SOURCE: Department of Surgery II, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan  
SOURCE: Cancer Letters (Shannon, Ireland) (2002), 175(1), 45-51  
CODEN: CALEDQ; ISSN: 0304-3835  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI-166  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:816651 CAPLUS  
DOCUMENT NUMBER: 135:358158  
TITLE: Preparation of N-[[4-(oxadiazol-2-yl)phenyl]sulfonyl]-amino acid derivatives having therapeutic or preventive efficacies against neoplastic disorders  
INVENTOR(S): Shinosaki, Toshihiro; Ninawa, Mitsuyoshi; Watanabe, Fumihiko  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl. No. 01/53 pp.  
CODEN: XXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083464	A1	20011108	WO 2001-JP3215	20010416
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			JP 2000-120235	A 20000421
OTHER SOURCE(S):			MARPAT 135:358158	

IT 372105-72-1P, (R)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-methylethanoic acid 372105-73-2P, (R)-2-[[[4-[3-Phenyl-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372105-75-4P, (R)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372105-76-5P, (R)-2-[[[4-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-methylethanoic acid 372105-77-7P, (R)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-methylethanoic acid 372105-79-8P, (R)-2-[[[4-[3-(4-Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372105-80-1P, (S)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372105-81-2P, (R)-2-[[[4-[3-Phenyl-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372105-82-3P, (R)-2-[[[4-[3-Phenyl-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-methylethanoic acid 372105-83-4P, (S)-2-[[[4-[3-(4-Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid 372105-84-5P, (R)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-85-6P, (S)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-86-7P, (R)-2-[[[4-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-87-8P, (R)-2-[[[4-[3-Phenyl-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-88-9P, (S)-2-[[[4-[3-Phenyl-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-89-0P, (R)-2-[[[4-[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-90-3P, (R)-2-[[[4-[3-(4-Trifluoromethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-91-4P, (R)-2-[[[4-[3-(4-tert-Butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-isopropylethanoic acid 372105-92-5P, (R)-2-[[[4-[3-(4-


L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-93-6P, (R)-2-[[[4-[3-(4-  
Butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-94-7P, (R)-2-[[[4-[3-(4-  
Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-95-8P, (S)-2-[[[4-[3-(4-  
Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-96-9P, (R)-2-[[[4-[3-(4-  
Isopropylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-97-0P, (R)-2-[[[4-[3-(4-  
Methylthiophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-98-1P, (R)-2-[[[4-[3-(4-  
Ethoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372105-99-2P, (R)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372106-00-8P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372106-01-9P, (R)-2-[[[4-[3-(4-Hydroxymethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-  
isopropylethanoic acid 372106-02-0P, (S)-2-[[[4-[3-Phenyl]-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-03-1P, (R)-2-[[[4-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-04-2P, (R)-2-[[[4-[3-(4-Dimethylamino)phenyl]-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-05-3P 372106-06-4P, (S)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-07-5P, (R)-2-[[[4-[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-08-6P, (R)-2-[[[4-[3-(4-Butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-09-7P, (R)-2-[[[4-[3-(4-Isopropylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-10-0P, (R)-2-[[[4-[3-(4-Methylthiophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-11-1P, (R)-2-[[[4-[3-(4-Trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-13-3P, (R)-2-[[[4-[3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-14-4P, (R)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-16-6P, (R)-2-[[[4-[3-(4-Pyrrolidin-1-yl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-17-7P, (R)-2-[[[4-[3-(4-Hydroxymethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-18-8P, (S)-2-[[[4-[3-(4-Hydroxymethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-19-9P, (R)-2-[[[4-[3-(3-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-benzylethanoic acid 372106-20-2P, (S)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-21-3P, (R)-2-[[[4-[3-(4-Isopropylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-22-4P, (R)-2-[[[4-[3-(4-Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-23-5P, (R)-2-[[[4-[3-(4-Trifluoromethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-24-6P, (R)-2-[[[4-[3-(4-Methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-25-7P,

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
(R)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-26-8P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-27-9P, (R)-2-[[[4-[3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-28-0P, (R)-2-[[[4-[3-(4-Methylthiophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-29-1P, (R)-2-[[[4-[3-(4-Nitrophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-30-4P, (R)-2-[[[4-[3-(4-Hydroxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-31-5P, (R)-2-[[[4-[3-(4-Hydroxymethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-32-6P, (R)-2-[[[4-[3-(4-Carboxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-methylethanoic acid 372106-33-7P, (R)-2-[[[4-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(2-methylthioethyl)ethanoic acid 372106-34-8P, (R)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(2-methylthioethyl)ethanoic acid 372106-47-3P, (R)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-48-4P, (S)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-49-5P, (R)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-50-8P, (R)-2-[[[4-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-51-9P, (R)-2-[[[4-[3-(4-Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-52-0P, (S)-2-[[[4-[3-(4-Ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-53-1P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-54-2P, (R)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(3-indolylmethyl)ethanoic acid 372106-55-3P, (R)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-isobutylethanoic acid 372106-56-4P, (S)-2-[[[4-[3-(4-Methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-isobutylethanoic acid 372106-57-5P, (R)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-isobutylethanoic acid 372106-58-6P, (R)-2-[[[4-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-isobutylethanoic acid 372106-59-7P, (S)-2-[[[4-[3-(4-Propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-isobutylethanoic acid 372106-60-0P, (R)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(4-hydroxybenzyl)ethanoic acid 372106-61-1P, (R)-2-[[[4-[3-Phenyl]-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]amino]-2-(4-hydroxybenzyl)ethanoic acid  
R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of [(oxadiazolyl)phenyl)sulfonyl]-amino acid derivs. as matrix metalloproteinase inhibitors and therapeutic or preventive agents for glomerular disorders)  
RN 372105-72-1 CAPLUS  
CN D-Alanine, N-[[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl)sulfonyl]-(CA INDEX NAME)]


L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
Absolute stereochemistry. Rotation (-).



Absolute stereochemistry. Rotation (+).




Absolute stereochemistry.




Absolute stereochemistry.


L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




Absolute stereochemistry.



Absolute stereochemistry.



Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372105-81-2 CAPLUS  
CN D-Tryptophan, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-82-3 CAPLUS  
CN D-Alanine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-83-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-84-5 CAPLUS  
CN D-Valine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-88-9 CAPLUS  
CN L-Valine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-89-0 CAPLUS  
CN D-Valine, N-[[4-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-90-3 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 372105-85-6 CAPLUS  
CN L-Valine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-86-7 CAPLUS  
CN D-Valine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-87-8 CAPLUS  
CN D-Valine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372105-91-4 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-92-5 CAPLUS  
CN D-Valine, N-[[4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-93-6 CAPLUS  
CN D-Valine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-94-7 CAPLUS  
CN D-Valine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-95-9 CAPLUS  
CN L-Valine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372105-96-9 CAPLUS  
CN D-Valine, N-[[4-[3-(4-(1-methylethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 372105-97-0 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(methylthio)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-98-1 CAPLUS  
CN D-Valine, N-[[4-[3-(4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372105-99-2 CAPLUS  
CN D-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 372106-00-8 CAPLUS  
CN L-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-01-9 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 372106-02-0 CAPLUS  
CN L-Phenylalanine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372106-03-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372106-04-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(dimethylamino)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 372106-05-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 372106-06-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372106-07-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

23 APR 2008




# 10824057 - Compound Search

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-08-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-09-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(1-methylethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-10-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(methylthio)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-11-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-13-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-14-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-15-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-(propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-16-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(1-pyrrolidinyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-17-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(hydroxymethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372106-18-8 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-(hydroxymethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-19-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-20-2 CAPLUS  
CN L-Alanine, N-[[4-[3-(4-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-21-3 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-(1-methylethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

23 APR 2008


# 10824057 - Compound Search

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-22-4 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-23-5 CAPLUS  
CN D-Alanine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-24-6 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-25-7 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-26-8 CAPLUS  
CN L-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-27-9 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-28-0 CAPLUS  
CN D-Alanine, N-[[4-[3-[4-(methylthio)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-29-1 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-30-4 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372106-31-5 CAPLUS  
CN D-Alanine, N-[[4-[3-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-32-6 CAPLUS  
CN Benzoic acid, N-[5-[4-[[[(1R)-1-carboxyethyl]amino]sulfonyl]phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-33-7 CAPLUS  
CN D-Methionine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-34-8 CAPLUS  
CN D-Methionine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-47-3 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-48-4 CAPLUS  
CN L-Tryptophan, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-49-5 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-53-1 CAPLUS  
CN L-Tryptophan, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-54-2 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-55-3 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-50-8 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-51-9 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-52-0 CAPLUS  
CN L-Tryptophan, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-56-4 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-57-3 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-58-2 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




## 10824057 - Compound Search

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372106-59-7 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 372106-60-0 CAPLUS  
CN D-Tyrosine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372106-61-1 CAPLUS  
CN D-Tyrosine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



IT 372492-53-0P, (R)-(-)-2-[[[4-[3-(4-Fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]amino]-2-benzylethanoic acid methyl ester  
RL: RC (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 2001:816650 CAPLUS  
DOCUMENT NUMBER: 135:357931  
TITLE: Preparation of oxadiazole derivatives as anticancer agents inhibiting MMP-2  
INVENTOR(S): Yoshioka, Takayuki; Watanabe, Ryuji; Watanabe, Fumihiko  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 57 pp.  
CODEN: JMXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083463	A1	20011108	WO 2001-JP3214	20010416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001046916	A	20011112	AU 2001-46916	20010416
CA 2406685	A1	20021017	CA 2001-2406685	20010416
CA 2406685	C	20061031		
EP 1277744	A1	20030122	EP 2001-919938	20010416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001010211	A	20030603	BR 2001-10211	20010416
HU 2003000619	A2	20030728	HU 2003-619	20010416
HU 2003000619	A3	20060228		
AU 2001246916	B2	20041007	AU 2001-246916	20010416
RU 2275371	C2	20060427	RU 2002-130247	20010416
JP 3974781	B2	20070912	JP 2001-580892	20010416
ZA 2002008307	A	20031015	ZA 2002-8307	20021015
NO 2002005035	A	20021219	NO 2002-5035	20021018
NO 324868	B1	20071217		
MX 2002PA10325	A	20030425	MX 2002-PA10325	20021018
US 20030203940	A1	20031030	US 2002-257917	20021018
US 6720343	B2	20040413		
IN 2002CN01705	A	20050211	IN 2002-CN1705	20021018
US 20040122066	A1	20040624	US 2003-730946	20031210
PRIORITY APPLN. INFO.:			JP 2000-120234	A 20000421
			WO 2001-JP3214	W 20010416
			US 2002-257917	A3 20021018

OTHER SOURCE(S): MARPAT 135:357931

IT 372105-72-1P 372105-73-2P 372105-75-4P  
372105-76-5P 372105-78-7P 372105-79-8P  
372105-80-1P 372105-81-2P 372105-82-3P  
372105-83-4P 372105-84-5P 372105-85-6P  
372105-86-7P 372105-87-8P 372105-88-9P  
372105-89-0P 372105-90-3P 372105-91-4P  
372105-92-5P 372105-93-6P 372105-94-7P  
372105-95-8P 372105-96-9P 372105-97-0P  
372105-98-1P 372105-99-2P 372106-00-8P  
372106-01-9P 372106-02-0P 372106-03-1P  
372106-04-2P 372106-05-3P 372106-06-4P  
372106-07-5P 372106-08-6P 372106-09-7P  
372106-10-0P 372106-11-1P 372106-13-3P


23 APR 2008

L3 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

(prepn. of [(oxadiazolyl)phenylsulfonyl]-amino acid derivs. as matrix metalloproteinase inhibitors and therapeutic or preventive agents for glomerular disorders)

RN 372492-53-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

372106-14-4P 372106-15-5P 372106-16-6P  
372106-17-7P 372106-18-8P 372106-19-9P  
372106-20-2P 372106-21-3P 372106-22-4P  
372106-23-5P 372106-24-6P 372106-25-7P  
372106-26-8P 372106-27-9P 372106-28-0P  
372106-29-1P 372106-30-4P 372106-31-5P  
372106-32-6P 372106-33-7P 372106-34-8P  
372106-47-3P 372106-48-4P 372106-49-5P  
372106-50-8P 372106-51-9P 372106-52-0P  
372106-53-1P 372106-54-2P 372106-55-3P  
372106-56-4P 372106-57-5P 372106-58-6P  
372106-59-7P 372106-60-0P 372106-61-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of oxadiazole derivs. as anticancer agents inhibiting MMP-2)


RN 372105-72-1 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 372105-73-2 CAPLUS  
CN D-Phenylalanine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 372105-75-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-76-5 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-78-7 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372105-79-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-80-1 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-81-2 CAPLUS  
CN D-Tryptophan, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372105-82-3 CAPLUS  
CN D-Alanine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-83-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-84-5 CAPLUS  
CN D-Valine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-85-6 CAPLUS  
CN L-Valine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372105-86-7 CAPLUS  
CN D-Valine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-87-8 CAPLUS  
CN D-Valine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-88-9 CAPLUS  
CN L-Valine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-89-0 CAPLUS  
CN D-Valine, N-[[4-(3-bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-90-3 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-91-4 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372105-92-5 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-93-6 CAPLUS  
CN D-Valine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-94-7 CAPLUS  
CN D-Valine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372105-95-8 CAPLUS  
CN L-Valine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372105-96-9 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(1-methylethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372105-97-0 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(methylthio)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372105-98-1 CAPLUS  
CN D-Valine, N-[[4-[3-(4-ethoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372105-99-2 CAPLUS  
CN D-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-00-8 CAPLUS  
CN D-Valine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-01-9 CAPLUS  
CN D-Valine, N-[[4-[3-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-02-0 CAPLUS  
CN L-Phenylalanine, N-[[4-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-03-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-04-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-dimethylamino)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-05-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-06-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-07-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-08-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-09-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(1-methylethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-10-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(methylthio)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-11-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372106-13-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-14-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-15-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-16-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(4-(1-pyrrolidinyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-17-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-18-8 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-19-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-20-4 CAPLUS  
CN L-Alanine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-21-3 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-(1-methylethyl)phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-22-4 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-23-8 CAPLUS  
CN D-Alanine, N-[[4-[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-24-6 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-25-7 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372106-26-8 CAPLUS  
CN L-Alanine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-27-9 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-28-0 CAPLUS  
CN D-Alanine, N-[[4-[3-[4-(methylthio)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-29-1 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-30-4 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-hydroxyphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-31-5 CAPLUS  
CN D-Alanine, N-[[4-[3-[4-(hydroxymethyl)phenyl]-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-32-6 CAPLUS  
CN Benzoic acid, 4-[5-[4-[[[(1R)-1-carboxyethyl]amino]sulfonyl]phenyl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-33-7 CAPLUS  
CN D-Methionine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-34-8 CAPLUS  
CN D-Methionine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-47-3 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-48-4 CAPLUS  
CN L-Tryptophan, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-49-5 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-50-8 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-51-9 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-52-0 CAPLUS  
CN L-Tryptophan, N-[[4-[3-(4-ethylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372106-53-1 CAPLUS  
CN L-Tryptophan, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-54-2 CAPLUS  
CN D-Tryptophan, N-[[4-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-55-3 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-56-4 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-60-0 CAPLUS  
CN D-Tyrosine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-61-1 CAPLUS  
CN D-Tyrosine, N-[[4-[3-(3-phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 372106-86-0P 372106-88-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxadiazole derivs. as anticancer agents inhibiting MMP-2)  
RN 372106-86-0 CAPLUS  
CN D-Alanine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372106-57-5 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372106-58-6 CAPLUS  
CN D-Leucine, N-[[4-[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372106-59-7 CAPLUS  
CN L-Leucine, N-[[4-[3-(4-propylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 372106-88-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(phenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## 10824057 - Compound Search

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:816648 CAPLUS  
DOCUMENT NUMBER: 135:344729  
TITLE: Preparation of N-thiazolylphenylsulfonylamino acid and N-oxazolylphenylsulfonylamino acid derivatives as macrophage metalloelastase inhibitors  
INVENTOR(S): Furue, Shingo; Watanabe, Fumihiko; Tamura, Yoshinori  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 67 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083461	A1	20011108	WO 2001-JP3437	20010423
W: AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.: JP 2000-130041 A 20000428 JP 2000-293419 A 20000927				

OTHER SOURCE(S): MARPAT 135:344729  
IT 370597-43-6P 370597-44-7P 370597-45-8P  
370597-56-1P 370597-62-9P 370597-63-0P  
370597-64-1P 370597-65-2P 370597-66-3P  
370597-67-4P 370597-69-6P 370597-71-0P  
370597-72-1P 370597-73-2P 370597-76-5P  
370597-77-6P 370597-80-1P 370597-83-4P  
370597-84-5P 370597-85-6P 370597-86-7P  
370597-87-8P 370597-88-9P 370597-89-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-thiazolylphenylsulfonylamino acid and N-oxazolylphenylsulfonylamino acid derivs. as macrophage metalloelastase inhibitors)

RN 370597-43-6 CAPLUS  
CN D-Alanine, N-[[4-[2-(2-naphthalenyl)-4-oxazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-44-7 CAPLUS  
CN D-Alanine, N-[[4-(2-phenyl-4-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-45-8 CAPLUS  
CN L-Alanine, N-[[4-(2-phenyl-4-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 370597-56-1 CAPLUS  
CN D-Valine, N-[[4-[4-(2-naphthalenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-62-9 CAPLUS  
CN D-Alanine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 370597-63-0 CAPLUS  
CN D-Alanine, N-[[4-[2-(2-phenyl-4-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-64-1 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-fluorophenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 370597-65-2 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-methylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-66-3 CAPLUS  
CN L-Alanine, N-[[4-[2-(4-methylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-67-4 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-methoxyphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-69-6 CAPLUS  
CN D-Alanine, N-[[4-[2-(3-methylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

23 APR 2008


# 10824057 - Compound Search

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-71-0 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-bromophenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-72-1 CAPLUS  
CN D-Alanine, N-[[4-[2-[4-(methylthio)phenyl]-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 370597-73-2 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-chlorophenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-76-5 CAPLUS  
CN D-Alanine, N-[[4-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-77-6 CAPLUS  
CN D-Alanine, N-[[4-[2-(1,3-benzodioxol-5-yl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 370597-80-1 CAPLUS  
CN D-Alanine, N-[[4-[2-(6-methoxy-2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-83-4 CAPLUS  
CN D-Valine, N-[[4-[2-(2-phenyl-4-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-84-5 CAPLUS  
CN D-Valine, N-[[4-[2-(4-fluorophenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-85-6 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 370597-86-7 CAPLUS  
CN D-Valine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-87-8 CAPLUS  
CN L-Valine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-88-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-methylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-89-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IT 370598-01-9P 370598-03-1P 370598-05-3P  
370598-06-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of N-thiazolylphenylsulfonylamino acid and N-oxazolylphenylsulfonylamino acid derivs. as macrophage metalloelastase inhibitors)  
RN 370598-01-9 CAPLUS  
CN D-Alanine, N-[[4-[2-(2-naphthalenyl)-4-oxazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 370598-03-1 CAPLUS  
CN D-Valine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 370598-05-3 CAPLUS  
CN D-Valine, N-[[4-[4-(2-naphthalenyl)-2-thiazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-47-0 CAPLUS  
CN L-Phenylalanine, N-[[4-(2-phenyl-4-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-48-1 CAPLUS  
CN D-Valine, N-[[4-(2-phenyl-4-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-50-5 CAPLUS  
CN D-Valine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).



RN 370598-06-4 CAPLUS  
CN D-Alanine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 370597-46-9P 370597-47-0P 370597-48-1P  
370597-50-5P 370597-51-6P 370597-52-7P  
370597-53-8P 370597-54-9P 370597-55-0P  
370597-57-2P 370597-58-3P 370597-59-4P  
370597-60-7P 370597-61-8P 370597-68-5P  
370597-70-9P 370597-74-3P 370597-90-3P  
370597-93-6P 370597-94-7P 370597-95-8P  
370597-96-9P 370597-97-0P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-thiazolylphenylsulfonylamino acid and N-oxazolylphenylsulfonylamino acid derivs. as macrophage metalloelastase inhibitors)  
RN 370597-46-9 CAPLUS  
CN D-Phenylalanine, N-[[4-(2-phenyl-4-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 370597-51-6 CAPLUS  
CN L-Valine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-52-7 CAPLUS  
CN D-Phenylalanine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-53-8 CAPLUS  
CN L-Phenylalanine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-54-9 CAPLUS  
CN D-Alanine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-55-0 CAPLUS  
CN L-Alanine, N-[[4-(2-phenyl-5-oxazolyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-57-2 CAPLUS  
CN D-Alanine, N-[[4-(4-phenyl-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 370597-58-3 CAPLUS  
CN D-Valine, N-[[4-(4-phenyl-2-thiazolyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-59-4 CAPLUS  
CN D-Valine, N-[[4-[4-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-60-7 CAPLUS  
CN D-Alanine, N-[[4-[4-(4-fluorophenyl)-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 370597-61-8 CAPLUS  
CN D-Valine, N-[[4-[4-(1-pyrrolidinyl)phenyl]-2-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-69-5 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-ethylphenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-70-9 CAPLUS  
CN D-Alanine, N-[[4-[2-[4-(1-methylethyl)phenyl]-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-74-3 CAPLUS  
CN D-Alanine, N-[[4-[2-[4-(dimethylamino)phenyl]-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 370597-90-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-93-6 CAPLUS  
CN D-Methionine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 370597-94-7 CAPLUS  
CN D-Serine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 370597-95-8 CAPLUS  
CN D-Leucine, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 370597-96-9 CAPLUS  
CN D-Aspartic acid, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 370597-97-0 CAPLUS  
CN D-Glutamic acid, N-[[4-[2-(2-naphthalenyl)-4-thiazolyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:816618 CAPLUS  
DOCUMENT NUMBER: 135:358157  
TITLE: Preparation of N-(arylsulfonyl) or N-(heteroarylsulfonyl)amino acid derivatives as matrix metalloproteinase-12 (MMP-12) inhibitors  
INVENTOR(S): Hori, Yozo; Watanabe, Fumihiko; Tsuzuki, Hiroshige; Furue, Shingo; Tamura, Yoshinori  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 62 pp.  
CODEN: PIXX2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083431	A1	20011108	WO 2001-JP3438	20010423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SN, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001048821	A	20011112	AU 2001-48821	20010423
EP 1288199	A1	20030305	EP 2001-921985	20010423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030158155	A1	20030821	US 2002-257478	20021015
US 6897237	B2	20050524		

PRIORITY APPLN. INFO.: JP 2000-130042 A 20000428  
JP 2000-293420 A 20000927  
WO 2001-JP3438 W 20010423  
OTHER SOURCE(S): MARPAT 135:358157  
IT 372160-38-8P 372160-39-9P 372160-42-4P,  
(R)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-benzylethanoic acid 372160-43-5P, (S)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-benzylethanoic acid 372160-45-7P, (R)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-methylethanoic acid 372160-46-8P, (S)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-methylethanoic acid 372160-47-9P, (R)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-isopropylethanoic acid 372160-48-0P, (S)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-isopropylethanoic acid 372160-49-1P, (R)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-isobutylethanoic acid 372160-50-4P, (S)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-isobutylethanoic acid 372160-51-5P, (R)-2-(((4-(5-(2-Naphthyl)-1,2,4-oxadiazol-3-yl)phenyl)sulfonyl)amino)-2-(3-indolylmethyl)ethanoic acid 372160-52-6P, (R)-2-(((4-(4-(2-Naphthyl)-1,3,5-oxadiazol-2-yl)phenyl)sulfonyl)amino)-2-benzylethanoic acid 372160-53-7P, (S)-2-(((4-(4-(2-Naphthyl)-1,3,5-oxadiazol-2-yl)phenyl)sulfonyl)amino)-2-benzylethanoic acid 372160-54-8P, (R)-2-(((4-(5-(2-Naphthyl)-1,3,4-oxadiazol-2-yl)phenyl)sulfonyl)amino)-2-isopropylethanoic acid


L3 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of (arylsulfonyl) or (heteroarylsulfonyl)amino acid derivs. as matrix metalloproteinase-12 inhibitors for prevention or treatment of chronic obstructive lung disease)  
RN 372160-38-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 372160-39-9 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 372160-42-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 372160-43-5 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372160-45-7 CAPLUS  
CN D-Alanine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 372160-46-8 CAPLUS  
CN L-Alanine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372160-47-9 CAPLUS  
CN D-Valine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




23 APR 2008

# 10824057 - Compound Search

L3 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 372160-48-0 CAPLUS  
CN L-Valine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 372160-49-1 CAPLUS  
CN D-Leucine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372160-50-4 CAPLUS  
CN L-Leucine, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 372160-51-5 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(2-naphthalenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 372160-52-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[3-(2-naphthalenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 372160-53-7 CAPLUS  
CN L-Phenylalanine, N-[[4-[3-(2-naphthalenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 372160-54-8 CAPLUS  
CN D-Valine, N-[[4-[5-(2-naphthalenyl)-1,3,4-oxadiazol-2-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:611767 CAPLUS  
DOCUMENT NUMBER: 135:180946  
TITLE: Preparation of sulfonylamino acid derivatives and sulfonylamino hydroxamic acid derivatives as inhibitors of matrix metalloproteinases  
INVENTOR(S): Kukkola, Paivi Jaana; Robinson, Leslie Anne; Nakajima, Motowo; Sakaki, Junichi  
PATENT ASSIGNEE(S): Novartis A.-G., Switzerland  
SOURCE: U.S., 38 pp.  
CODEN: USX60M  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUN.: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6277987	B1	20010821	US 1999-243854	19990203
PRIORITY APPLN. INFO.:			US 1998-135514P	P 19980204
OTHER SOURCE(S):		MARPAT 135:180946		
IT 240135-30-2P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of sulfonylamino acids and sulfonylamino hydroxamic acids as inhibitors of matrix metalloproteinases)				
RN 240135-30-2 CAPLUS				
CN 1,2-Benzisothiazole-2(3H)-pentanoic acid, 3-oxo- $\alpha$ -[[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]amino]-, 1,1-dioxide, ( $\alpha$ R)- (CA INDEX NAME)				

Absolute stereochemistry.




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



## 10824057 - Compound Search

L3 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:577155 CAPLUS  
DOCUMENT NUMBER: 135:327070  
TITLE: Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer  
AUTHOR(S): Ohta, Manabu; Konno, Hiroyuki; Tanaka, Tatsuo; Baba, Megumi; Kamiya, Kinji; Oba, Kouji; Waneke, Takeshi; Syouji, Tsuyoshi; Igarashi, Akio; Nakamura, Satoshi  
CORPORATE SOURCE: Department of Surgery II, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan  
SOURCE: Japanese Journal of Cancer Research (2001), 92(6), 688-695  
CODEN: JJCRAN; ISSN: 0910-5050  
PUBLISHER: Japanese Cancer Association  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI-166  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effect of combination therapy with MMI-166 and mitomycin C on growth and liver metastasis of human colon cancer)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:569633 CAPLUS  
DOCUMENT NUMBER: 135:137709  
TITLE: Preparation of L and D-tryptophan derivatives and prodrugs  
INVENTOR(S): Watanabe, Fumihiko  
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055133	A1	20010802	WO 2001-JP412	20010123
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EF, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KB, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001027090	A1	20010807	AU 2001-27090	20010123
EP 1270569	A1	20030102	EP 2001-901512	20010123
R:	AT, BE, CA, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003013032	A1	20030710	US 2002-169836	20020710
US 6727266	B2	20040427		

PRIORITY APPLN. INFO.: JP 2000-16370 A 20000126  
WO 2001-JP412 W 20010123


OTHER SOURCE(S): MARPAT 135:137709  
IT 352036-08-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of D-tryptophan derivs. and prodrugs)  
RN 352036-08-9 CAPLUS  
CN D-Tryptophan, 5-methoxy-N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




L3 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
IT 352036-09-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of tryptophan derivs. and prodrugs)  
RN 352036-09-0 CAPLUS  
CN L-Tryptophan, 5-fluoro-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 352036-10-3P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of tryptophan derivs. and prodrugs)  
RN 352036-10-3 CAPLUS  
CN L-Tryptophan, 5-fluoro-N-[[4-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2001:301185 CAPLUS  
DOCUMENT NUMBER: 135:235988  
TITLE: Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer  
AUTHOR(S): Matsushita, A.; Onda, M.; Uchida, E.; Maekawa, R.; Yoshioka, T.  
CORPORATE SOURCE: Department of Surgery I, Nippon Medical School, Tokyo, 113-8603, Japan  
SOURCE: International Journal of Cancer (2001), 92(3), 434-440  
CODEN: IJCNAA; ISSN: 0000-7136  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193809-84-6, MMI 166  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(matrix metalloproteinase inhibitor MMI-166 inhibition of pancreatic cancer)  
RN 193809-84-6 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

# 10824057 - Compound Search

L3 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:102974 CAPLUS  
 DOCUMENT NUMBER: 135:146871  
 TITLE: Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor  
 AUTHOR(S): Maekawa, Ryuji; Maki, Hideo; Wada, Tohru; Yoshida, Hiroshi; Nishida-Nishimoto, Kazuyo; Okamoto, Hiroyuki; Matsumoto, Yayoi; Tsuruta, Hiroshige; Yoshioka, Takayuki  
 CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi and Co., Ltd, Osaka, 553-0002, Japan  
 SOURCE: Clinical & Experimental Metastasis (2000), 18(1), 61-66  
 CODEN: CEMD2; ISSN: 0262-0898  
 PUBLISHER: Kluwer Academic Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 193809-84-6, MMI 166, a selective matrix metalloproteinase inhibitor, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antimastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor)  
 RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:830403 CAPLUS  
 DOCUMENT NUMBER: 134:538  
 TITLE: Sulfonamide inhibitors of matrix metalloproteinases, their preparation, and their therapeutic use  
 INVENTOR(S): Ortwine, Daniel F.; Purchas, Claude F., Jr.; White, Andrew D.  
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
 SOURCE: U.S., 19 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:  

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6153612	A	20001128	US 1999-412707	19991005
US 6297247	B1	20011002	US 2000-599306	20000622
PRIORITY APPLN. INFO:			US 1995-7372P	P 19951117
			WO 1996-US16761	A3 19961018
			US 1999-412707	A3 19991005

 OTHER SOURCE(S): MARPAT 134:538  
 IT 191474-97-2P 191475-00-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (sulfonamide inhibitors of matrix metalloproteinases, preparation, and therapeutic use)  
 RN 191474-97-2 CAPLUS  
 CN L-Tyrosine, O-(phenylmethyl)-N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 191475-00-0 CAPLUS  
 CN L-Phenylalanine, N-[[4-(4-(3-methoxyphenyl)-1-piperazinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




IT 191474-88-1P 191474-89-2P 191474-90-5P  
 191474-91-6P 191474-92-7P 191474-93-8P  
 191474-98-3P 191474-99-4P 191475-01-1P  
 191475-02-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (sulfonamide inhibitors of matrix metalloproteinases, preparation, and therapeutic use)  
 RN 191474-88-1 CAPLUS  
 CN D-Leucine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 191474-89-2 CAPLUS  
 CN L-Leucine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 191474-90-5 CAPLUS


L3 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 191474-91-6 CAPLUS  
 CN D-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 191474-92-7 CAPLUS  
 CN L-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 191474-93-8 CAPLUS  
 CN Benzenepentanoic acid, α-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonylamino]- (CA INDEX NAME)


# 10824057 - Compound Search

L3 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 191474-98-3 CAPLUS  
CN L-Tyrosine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 191474-99-4 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperazinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 191475-01-1 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(3-hydroxyphenyl)-1-piperazinyl]phenyl]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 191475-07-7 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-chlorophenyl)-1-piperazinyl]phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 191475-02-2 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 191475-06-6 191475-07-7  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sulfonamide inhibitors of matrix metalloproteinases, preparation, and therapeutic use)

RN 191475-06-6 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2000:756693 CAPLUS  
DOCUMENT NUMBER: 133:309896  
TITLE: Preparation of sulfonamide derivatives having oxadiazole rings as matrix metalloprotease inhibitors  
INVENTOR(S): Watanabe, Fumihiko; Tamura, Yoshio; Fujii, Yasuhiko  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 47 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063194	A1	20001001	WO 2000-JP2404	20000413
W:	AE, AG, AL, AM, AT, AU, BE, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DO, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RO, TJ, TM			
FW:	GH, GM, KE, LU, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2367395	A1	20001026	CA 2000-2367395	20000413
EP 1172361	A1	20020116	EP 2000-915504	20000413
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
AU 765203	B2	20030911	AU 2000-36776	20000413
US 6435078	B1	20021217	US 2001-959008	20011017
WO 2001005078	A	20011218	WO 2001-5078	20011018
PRIORITY APPLN. INFO.:			JP 1999-110321	A 19990419
			WO 2000-JP2404	W 20000413

OTHER SOURCE(S): MARPAT 133:309896  
IT 301835-44-9P 301835-45-0P 301835-46-1P  
301835-47-2P 301835-48-3P 301835-49-4P  
301835-50-7P 301835-51-8P 301835-52-9P  
301835-53-0P 301835-54-1P 301835-58-5P  
301835-59-6P 301835-60-9P 301835-61-0P  
301835-62-1P 301835-63-2P 301835-71-2P  
301835-72-3P 301835-73-4P 301835-74-5P  
301835-75-6P 301835-76-7P 301835-77-8P  
301835-78-9P 301835-79-0P 301835-80-3P  
301835-81-4P 301835-86-9P 301835-87-0P  
301835-88-1P 301835-89-2P 301835-90-5P  
301835-91-6P 301835-92-7P 301835-93-8P  
301836-06-6P 301836-07-7P 301836-08-8P  
301836-09-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of sulfonamide derivs. having oxadiazole rings as matrix metalloprotease inhibitors)  
RN 301835-44-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


# 10824057 - Compound Search

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-45-0 CAPLUS  
CN D-Valine, N-[[4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-46-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 301835-47-2 CAPLUS  
CN D-Valine, N-[[4-[5-(4-butylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-48-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-49-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 301835-50-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-51-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-(dimethylamino)phenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-52-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-butylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-53-0 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 301835-54-1 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-58-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-59-6 CAPLUS  
CN D-Valine, N-[[4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-60-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

23 APR 2008


## 10824057 - Compound Search

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-61-0 CAPLUS  
CN L-Valine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 301835-62-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 301835-63-2 CAPLUS  
CN L-Valine, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-71-2 CAPLUS  
CN D-Phenylalanine, N-[[4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 301835-72-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 301835-73-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-74-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 301835-75-6 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 301835-76-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-cyanophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 301835-77-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-cyclohexylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 301835-78-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(3-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 301835-79-0 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(1,3-benzodioxol-5-yl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 301835-80-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.

23 APR 2008


# 10824057 - Compound Search

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-81-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(3,4-dichlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-86-9 CAPLUS  
CN D-Alanine, N-[[4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 301835-87-0 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-91-6 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-92-7 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-nitrophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-93-8 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-acetylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




23 APR 2008

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 301835-88-1 CAPLUS  
CN L-Alanine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301835-89-2 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301835-90-5 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 301836-06-6 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(4-ethylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301836-07-7 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(4-propylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 301836-08-8 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 301836-69-1 CAPLUS  
CN L-Leucine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 301836-27-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of sulfonamide derivs. having oxadiazole rings as matrix metalloprotease inhibitors)  
 RN 301836-27-1 CAPLUS  
 CN D-Valine, N-[[4-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:190916 CAPLUS  
 DOCUMENT NUMBER: 132:236806  
 TITLE: Preparation of remedial or preventive agents for congestive heart failure  
 INVENTOR(S): Watanabe, Toshiro; Gemba, Takefumi; Tsuzuki, Hiroshi; Shimamura, Toshitake  
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000015213	AI	20000323	WO 1999-JP4859	19990908
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9956470	AI	20000403	AU 1999-56470	19990908
PRIORITY APPLN. INFO.:			JP 1998-258033	A 19980911
			WO 1999-JP4859	W 19990908
OTHER SOURCE(S):		MARPAT 132:236806		
IT 220043-14-1P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of remedial or preventive agents for congestive heart failure)				
RN 220043-14-1 CAPLUS				
CN D-Valine, N-[[4-[2-[4-(2-hydroxyethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)				

Absolute stereochemistry. Rotation (-).




IT 193809-82-4P 193809-84-6P 193809-85-7P  
 193809-88-0P 193809-89-1P 193809-91-5P  
 193809-93-7P 193809-94-8P 193809-95-9P  
 193809-96-0P 193809-97-1P 193809-98-2P  
 193809-99-3P 193810-00-3P 193810-01-4P  
 193810-02-5P 193810-03-6P 193810-04-7P

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


193810-05-8P 193810-06-9P 193810-07-0P  
 193810-08-1P 193810-09-2P 193810-10-5P  
 193810-11-6P 193810-12-7P 193810-13-8P  
 193810-14-9P 193810-15-0P 193810-16-1P  
 193810-17-2P 193810-18-3P 193810-19-4P  
 193810-20-7P 193810-26-3P 193810-27-4P  
 220043-09-4P 220043-11-8P 220043-12-9P  
 220043-13-0P 220043-15-2P 220043-16-3P  
 220043-17-4P 220043-18-5P 220043-19-6P  
 220043-20-9P 220043-21-0P 220043-22-1P  
 220043-23-2P 220043-24-3P 220043-25-4P  
 220043-26-5P 220043-28-7P 220043-29-8P  
 220043-61-8P 220043-62-9P 220043-63-0P  
 220043-64-1P 220043-65-2P 220043-67-4P  
 220043-69-6P 220043-70-9P 220043-71-0P  
 220043-72-1P 220043-74-3P 220043-75-4P  
 220043-76-5P 220043-77-6P 220043-78-7P  
 261757-62-4P 261757-83-9P 261758-40-1P  
 261758-41-2P 261758-42-3P 261758-43-4P  
 261758-44-5P 261758-45-6P 261758-46-7P  
 261758-47-8P 261758-48-9P 261759-17-5P  
 261759-18-6P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of remedial or preventive agents for congestive heart failure)  
 RN 193809-82-4 CAPLUS  
 CN D-Valine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193809-85-7 CAPLUS

23 APR 2008


L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 CN D-Phenylalanine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193809-88-0 CAPLUS  
 CN D-Leucine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193809-89-1 CAPLUS  
 CN D-Valine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193809-91-5 CAPLUS  
 CN [1,1'-Biphenyl]-4-propanoic acid,  $\alpha$ -[[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193809-93-7 CAPLUS  
CN D-Tryptophan, 1-formyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 193809-94-8 CAPLUS  
CN D-Tryptophan, 1-formyl-N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193809-95-9 CAPLUS  
CN D-Isoleucine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA  
INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193809-96-0 CAPLUS  
CN D-Isoleucine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 193809-97-1 CAPLUS  
CN D-Valine, N-[[4-[2-(4-hydroxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 193809-98-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193809-99-3 CAPLUS  
CN D-Valine, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA  
INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193810-00-3 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-3-  
methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-01-4 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-02-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-  
yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-03-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-(trifluoromethyl)phenyl]-2H-tetrazol-5-  
yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 193810-04-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-nitrophenyl)-2H-tetrazol-5-  
yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-05-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193810-06-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-chlorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-07-0 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-08-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-09-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-cyanophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-10-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-(1,1-dimethylethyl)phenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-11-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-cyclohexylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193810-12-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-phenoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-13-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-hydroxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-14-9 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193810-15-0 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 193810-16-1 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-17-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193810-18-3 CAPLUS  
CN D-Valine, N-[[4-[2-(4-chlorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-19-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-20-7 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-26-3 CAPLUS  
CN D-Valine, N-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-27-4 CAPLUS  
CN D-Leucine, N-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-09-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-azidoethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 220043-11-8 CAPLUS  
CN D-Valine, N-[[4-[2-(4-hydroxyethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-12-9 CAPLUS  
CN D-Valine, N-[[4-[2-(4-ethylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 220043-13-0 CAPLUS  
CN D-Valine, N-[[4-[2-(4-butyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-15-2 CAPLUS  
CN D-Glutamine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-16-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 220043-17-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

23 APR 2008


# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-18-5 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-19-6 CAPLUS  
CN D-Leucine, N-[[4-[2-[4-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-20-9 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(4-cyanophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-21-0 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(4-butoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-22-1 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(aminocarbonyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-23-2 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(4-acetylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-24-3 CAPLUS  
CN D-Alanine, N-[[4-[2-[4-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 220043-25-4 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(acetylamino)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-26-5 CAPLUS  
CN D-Methionine, N-[[4-[2-[4-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 220043-28-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-(4-butoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-29-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-(4-acetylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-61-8 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-62-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-[4-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-63-8 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-64-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-65-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-67-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 220043-69-6 CAPLUS  
CN L-Valine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 220043-70-9 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-71-0 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 220043-73-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 220043-74-3 CAPLUS  
CN D-Valine, N-[[4-[5-(4-phenyl-2H-tetrazol-2-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 220043-75-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethoxyphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-76-5 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(dimethylamino)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-77-6 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(methylthio)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-78-7 CAPLUS  
CN D-Valine, N-[[4-[5-(4-butylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 261757-62-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 261757-83-9 CAPLUS  
CN D-Valine, N-[[4-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 261758-40-1 CAPLUS  
CN D-Tryptophan, 1-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 261758-41-2 CAPLUS  
CN D-Tryptophan, 5-fluoro-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 261758-42-3 CAPLUS  
CN D-Tryptophan, 4-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 261758-43-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-aminophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 261758-44-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-mercaptophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 261758-45-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-formylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 261758-46-7 CAPLUS  
CN 1-Naphthalenepropanoic acid,  $\alpha$ -[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]amino]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 261758-47-8 CAPLUS  
CN Tryptophan, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 261758-48-9 CAPLUS  
CN Tryptophan, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 261759-17-5 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 261759-18-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-butylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

# 10824057 - Compound Search

L3 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:579153 CAPLUS  
 DOCUMENT NUMBER: 131:214280  
 TITLE: Preparation of sulfonamides as MMP-8 inhibitors  
 INVENTOR(S): Watanabe, Fumihiko; Tsumiki, Hiroshi  
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 2000-117 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11246527	A	19990914	JP 1998-49260	19980302
JP 1998-49260			JP 1998-49260	19980302


PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S): MARPAT 131:214280  
 IT 193809-84-6P 193809-85-7P 193809-98-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of sulfonamides as MMP-8 inhibitors)  
 RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193809-85-7 CAPLUS  
 CN D-Phenylalanine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



L3 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 193809-98-2 CAPLUS  
 CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:549253 CAPLUS  
 DOCUMENT NUMBER: 131:184961  
 TITLE: Preparation of 1,2-benzisothiazole, quinazoline, imidazole, and morpholine sulfonylamino derivatives as matrix-degrading metalloproteinase inhibitors  
 INVENTOR(S): Kukkola, Paivi; Linn, Robinson, Leslie Anne; Sakaki, Junichi; Nakajima, Motowo  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.  
 SOURCE: PCT Int. Appl., 87 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942443	A1	19990826	WO 1999-EP646	19990202
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2318145	A1	19990826	CA 1999-2318145	19990202
AU 9929235	A	19990906	AU 1999-29235	19990202
AU 747911	B2	20020530		
EP 1053226	A1	20001122	EP 1999-910174	19990202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9909322	A	20001205	BR 1999-9322	19990202
TR 200002224	T2	20001221	TR 2000-2224	19990202
HU 2001001176	A2	20010928	HU 2001-1176	19990202
JP 2002503720	T	20020205	JP 2000-532395	19990202
NZ 505968	A	20030328	NZ 1999-505968	19990202
RU 2208609	C2	20030720	RU 2000-123166	19990202
NO 2000003565	A	20001003	NO 2000-3565	20000711
NO 317977	B1	20050117		
IN 2000CN00225	A	20050304	IN 2000-CN225	20000728
US 6410580	B1	20020625	US 2000-601462	20000802
MX 2000PA07679	A	20010219	MX 2000-PA7679	20000804
PRIORITY APPLN. INFO.:			US 1998-18819	A 19980204
			WO 1999-EP646	W 19990202

OTHER SOURCE(S): MARPAT 131:184961  
 IT 240135-30-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 1,2-benzisothiazole, quinazoline, imidazole, and morpholine sulfonylamino derivs. as matrix-degrading metalloproteinase inhibitors)  
 RN 240135-30-2 CAPLUS  
 CN 1,2-Benzisothiazole-2(3H)-pentanoic acid, 3-oxo- $\alpha$ -[[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]amino]-, 1,1-dioxide, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.

# 10824057 - Compound Search


L3 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:440505 CAPLUS  
 DOCUMENT NUMBER: 131:210917  
 TITLE: X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity  
 AUTHOR(S): Pavlovsky, Alexander G.; Williams, Mark G.; Ye, Qi-Zhuang; Ortwin, Daniel F.; Purchase, Claude F.; White, Andrew D.; Dhanaraj, V.; Roth, Bruce D.; Johnson, Linda L.; Hupe, Donald; Humblet, Christine; Blundell, Tom L.  
 CORPORATE SOURCE: Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA  
 SOURCE: Protein Science (1999), 8(7), 1455-1462  
 CODEN: PRCLIE; ISSN: 0961-8368  
 PUBLISHER: Cambridge University Press  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 191474-92-7 242816-44-0  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors)  
 RN 191474-92-7 CAPLUS  
 CN L-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 242816-44-0 CAPLUS  
 CN D-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:421569 CAPLUS  
 DOCUMENT NUMBER: 131:68144  
 TITLE: Angiotensin-converting enzyme inhibitor-matrix metalloproteinase inhibitor combinations for treatment of fibrosis, ventricular dilation, and heart failure  
 INVENTOR(S): Peterson, Joseph Thomas, Jr.; Pressler, Milton Lethan  
 PATENT ASSIGNEE(S): Warner-Lambert Company, USA  
 SOURCE: PCT Int. Appl. No. 98/000000 PP.  
 CODEN: PCTEPP  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932150	A1	19990701	WO 1998-US23993	19981110
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305436	A1	19990701	CA 1998-2305436	19981110
AU 9915220	A	19990712	AU 1999-15220	19981110
AU 751701	B2	20020822		
BR 9814422	A	20001010	BR 1998-14422	19981110
EP 1047450	A1	20001102	EP 1998-959416	19981110
EP 1047450	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
HU 2001000427	A2	20010628	HU 2001-427	19981110
HU 2001000427	A3	20021128		
JP 2001526245	T	20011218	JP 2000-525140	19981110
NZ 503962	A	20020328	NZ 1998-503962	19981110
AT 225187	T	20021015	AT 1998-959416	19981110
ES 2184340	T3	20030401	ES 1998-959416	19981110
ZA 9811794	A	19990629	ZA 1998-11794	19981222
US 6133304	A	20001017	US 2000-485253	20000207
MX 200003736	A	20001020	MX 2000-3736	20000417
NO 2000003256	A	20000622	NO 2000-3256	20000622
PRIORITY APPLN. INFO.:			US 1997-68594P	P 19971223
			WO 1998-US23993	W 19981110

OTHER SOURCE(S): MARPAT 131:68144  
 IT 191474-90-5 191475-02-2  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (ACE inhibitor-matrix metalloproteinase inhibitor combinations for treatment of fibrosis, ventricular dilation, and heart failure)  
 RN 191474-90-5 CAPLUS  
 CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 191475-02-2 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## No tetrazole in instnat at A-ring

L3 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1999:255446 CAPLUS  
DOCUMENT NUMBER: 131:70224  
TITLE: Homology Modeling of Gelatinase Catalytic Domains and Docking Simulations of Novel Sulfonamide Inhibitors  
AUTHOR(S): Kiyama, Ryuichi; Tamura, Yoshinori; Watanabe, Fumihiko; Tsuzuki, Hiroshi; Ohtani, Mitsuaki; Yodo, Mitsuaki  
CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi Company Ltd., Sagami Fukushima-cho, Osaka, 553-0002, Japan  
SOURCE: Journal of Medicinal Chemistry (1999), 42(10), 1723-1738  
CODEN: JMCBER; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 229165-82-6  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); NUU (Other use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)  
(homol. modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors)  
RN 229165-82-6 CAPLUS  
CN L-Valine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




IT 229165-56-4 229165-57-5  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(homol. modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors)  
RN 229165-56-4 CAPLUS  
CN L-Valine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.


## No tetrazole in instnat at A-ring

L3 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 229165-57-5 CAPLUS  
CN L-Valine, N-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1999:96111 CAPLUS  
DOCUMENT NUMBER: 130:139649  
TITLE: Preparation and formulation of amino acid derivatives as therapeutic or prophylactic agents for glomerulopathy  
INVENTOR(S): Kurihara, Hidetake; Watanabe, Fumihiko; Tamura, Yoshinori; Sinosaki, Toshihiro  
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 102 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904780	A1	19990204	WO 1998-JP32	19980717
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, IL, IN, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VE, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, ZA, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2297011	A1	19990204	CA 1998-2297011	19980717
CA 2297011	C	20070130		
AU 9882439	A	19990216	AU 1998-82439	19980717
AU 737218	B2	20010809		
BR 9811521	A	20000822	BR 1998-11521	19980717
EP 1029541	A1	20000823	EP 1998-932574	19980717
EP 1029541	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL				
TR 200000214	T2	20000921	TR 2000-214	19980717
NZ 502274	A	20000330	NZ 1998-502274	19980717
HU 2000003851	A2	20010730	HU 2000-3851	19980717
HU 2000003851	A3	20021028		
TR 200100389	T2	20010821	TR 2001-389	19980717
RU 2207849	C2	20030710	RU 2000-103032	19980717
EP 1398027	A1	20040317	EP 2003-23547	19980717
EP 1398027	B1	20070110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL				
JP 3621427	B2	20050216	JP 1999-509649	19980717
AT 320801	T	20060415	AT 1998-932574	19980717
TW 593249	B	20040621	TW 1998-87111798	19980930
TW 249518	B	20060221	TW 2003-92118405	19980930
US 6423729	B1	20020723	US 1999-462001	19991230
NO 2000000285	A	20000322	NO 2000-285	20000120
MX 200000712	A	20001030	MX 2000-712	20000120
US 20030078434	A1	20030424	US 2002-162865	20020606
US 6878739	B2	20050412		
PRIORITY APPL. INFO.:				
OTHER SOURCE(S):		MARPAT 130:139649		
IT 193809-82-4P 193809-84-6P 193809-85-7P 193809-94-8P 193809-99-3P 193810-01-4P 193810-05-8P 193810-15-0P 193810-17-2P				
			JP 1997-195414	A 19970722
			EP 1998-932574	A3 19980717
			WO 1998-JP3226	W 19980717
			US 1999-462001	A3 19991230



# 10824057 - Compound Search

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


220043-09-4P 220043-11-8P 220043-12-9P  
220043-13-0P 220043-14-1P 220043-15-2P  
220043-16-3P 220043-17-4P 220043-18-5P  
220043-19-6P 220043-20-9P 220043-21-0P  
220043-22-1P 220043-23-2P 220043-24-3P  
220043-25-4P 220043-26-5P 220043-28-7P  
220043-29-8P 220043-60-7P 220043-61-8P  
220043-62-9P 220043-63-0P 220043-64-1P  
220043-65-2P 220043-66-3P 220043-67-4P  
220043-68-5P 220043-69-6P 220043-70-9P  
220043-71-0P 220043-72-1P 220043-74-3P  
220043-75-4P 220043-76-5P 220043-77-6P  
220043-78-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. amino acid derivs. as therapeutic or prophylactic agents for glomerulopathy)

RN 193809-84-4 CAPLUS

CN D-Valine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193809-84-6 CAPLUS

CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193809-85-7 CAPLUS

CN D-Phenylalanine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 193810-05-8 CAPLUS

CN D-Phenylalanine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193810-15-0 CAPLUS

CN D-Tryptophan, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 193810-17-2 CAPLUS

CN D-Valine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry. Rotation (-).



RN 193809-94-8 CAPLUS

CN D-Tryptophan, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193809-99-3 CAPLUS

CN D-Valine, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193810-01-4 CAPLUS

CN D-Tryptophan, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 220043-09-4 CAPLUS

CN D-Phenylalanine, N-[[4-[2-(4-azidoethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 220043-11-8 CAPLUS

CN D-Phenylalanine, N-[[4-[2-(4-(2-hydroxyethyl)phenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-12-9 CAPLUS

CN D-Valine, N-[[4-[2-(4-ethylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




## 10824057 - Compound Search

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 220043-13-0 CAPLUS  
CN D-Valine, N-[[4-[2-(4-butylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-14-1 CAPLUS  
CN D-Valine, N-[[4-[2-(4-(2-hydroxyethyl)phenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-15-2 CAPLUS  
CN D-Glutamine, N2-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- N-phenyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-16-3 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-20-9 CAPLUS  
CN D-Valine, N-[[4-[2-(4-cyanophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-21-0 CAPLUS  
CN D-Valine, N-[[4-[2-(4-butoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-22-1 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(aminocarbonyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




23 APR 2008

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-17-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 220043-18-5 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-19-6 CAPLUS  
CN D-Leucine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 220043-23-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-acetylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-24-3 CAPLUS  
CN D-Alanine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 220043-25-4 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(acetylamino)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 220043-26-5 CAPLUS  
CN D-Methionine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


## 10824057 - Compound Search

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-28-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-butoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-29-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-acetylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-60-7 CAPLUS  
CN D-Norvaline, N-[[4-[5-(4-methylphenyl)-2-thienyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-61-8 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-62-9 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 220043-63-0 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-64-1 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-65-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-66-3 CAPLUS  
CN D-Tryptophan, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-67-4 CAPLUS  
CN L-Phenylalanine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 220043-68-5 CAPLUS  
CN D-Valine, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 220043-69-6 CAPLUS  
CN L-Valine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


# 10824057 - Compound Search

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-70-9 CAPLUS  
CN D-Leucine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-71-0 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 220043-72-1 CAPLUS  
CN D-Phenylalanine, N-[[4-(5-phenyl-2H-tetrazol-2-yl)phenyl]sulfonyl]- (CA  
INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-74-3 CAPLUS  
CN D-Alanine, N-[[4-[5-(4-ethylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 220043-75-4 CAPLUS  
CN D-Valine, N-[[4-[5-(4-ethoxyphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 220043-76-5 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(dimethylamino)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 220043-77-6 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(methylthio)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 220043-78-7 CAPLUS  
CN D-Valine, N-[[4-[5-(4-butylphenyl)-2H-tetrazol-2-yl]phenyl]sulfonyl]- (CA  
INDEX NAME)


Absolute stereochemistry. Rotation (-).



IT 193810-45-6P 220043-80-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of amino acid derivs. as therapeutic or prophylactic agents for  
glomerulopathy)  
RN 193810-45-6 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 220043-80-1 CAPLUS  
CN D-Valine, N-[[4-[5-[4-(trifluoromethyl)phenyl]-2H-tetrazol-2-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

## 10824057 - Compound Search


L3 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1998:424117 CAPLUS  
DOCUMENT NUMBER: 129:113523  
TITLE: Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing  
INVENTOR(S): Bocan, Thomas Michael Andrew; Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David  
PATENT ASSIGNEE(S): Warner-Lambert Co., USA; Bocan, Thomas Michael Andrew; Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David  
SOURCE: PCT Int. Appl., 163 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826773	A1	19980625	WO 1997-US21532	19971121
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264692	A1	19980625	CA 1997-2264692	19971121
AU 9877353	A	19980715	AU 1998-77353	19971121
AU 737117	B2	20010809		
EP 946166	A1	19991006	EP 1997-949584	19971121
EP 946166	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9714142	A	20000229	BR 1997-14142	19971121
JP 2001507342	T	20010605	JP 1998-527715	19971121
NZ 334925	A	20010629	NZ 1997-334925	19971121
EP 1366765	A1	20031203	EP 2003-18081	19971121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
AT 259640	T	20040315	AT 1997-949584	19971121
PT 946166	T	20040630	PT 1997-949584	19971121
ES 2212142	T3	20040716	ES 1997-949584	19971121
ZA 9711279	A	19980623	ZA 1997-11279	19971215
US 6340709	B1	20020122	US 1999-269123	19990319
PRIORITY APPLN. INFO.:			US 1996-32753P	P 19961217
			EP 1997-949584	A3 19971121
			WO 1997-US21532	W 19971121

OTHER SOURCE(S): MARPAT 129:113523  
IT 191474-90-5 191475-02-2  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing)  
RN 191474-90-5 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


L3 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
INDEX NAME)

Absolute stereochemistry.



RN 191475-02-2 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1998:402296 CAPLUS  
DOCUMENT NUMBER: 129:76499  
TITLE: Method for treating and preventing heart failure and ventricular dilation  
INVENTOR(S): Peterson, Joseph T., Jr.  
PATENT ASSIGNEE(S): Warner-Lambert Co., USA  
SOURCE: PCT Int. Appl., 178 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825597	A2	19980618	WO 1997-US21934	19971202
WO 9825597	B1	20001012		
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2263886	A1	19980618	CA 1997-2263886	19971202
AU 9855906	A	19980703	AU 1998-55906	19971202
AU 741768	B2	20011206		
BR 9714385	A	20000516	BR 1997-14385	19971202
EP 1028716	A1	20000823	EP 1997-952246	19971202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 334897	A	20010223	NZ 1997-334897	19971202
JP 2001526631	T	20011218	JP 1998-526758	19971202
ZA 9711004	A	19981005	ZA 1997-11004	19971208
US 5948780	A	19990907	US 1997-987167	19971208
MX 9901974	A	20020327	MX 1999-1974	19990226
NO 9902769	A	19990809	NO 1999-2769	19990608
KR 2000057444	A	20000915	KR 1999-705070	19990608
PRIORITY APPLN. INFO.:			US 1996-32631P	P 19961209
			WO 1997-US21934	W 19971202

OTHER SOURCE(S): MARPAT 129:76499  
IT 191474-90-5 191475-02-2  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of matrix metalloproteinase inhibitors in treating heart failure and ventricular dilation)  
RN 191474-90-5 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 191475-02-2 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



# 10824057 - Compound Search

No tetrazole in instnat at A-ring

L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ACCESSION NUMBER: 1998:66723 CAPLUS

DOCUMENT NUMBER: 128:188290

TITLE: Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives

AUTHOR(S): Tamura, Yoshinori; Watanabe, Fumihiko; Nakatani, Takuji; Yasui, Ken; Fuji, Masahiro; Komurazaki, Tadafumi; Tsuzuki, Hiroshige; Maekawa, Ryuji; Yoshioke, Takayuki; Kawada, Kenji; Sugita, Kenji; Ohtani, Mitsuaki

CORPORATE SOURCE: Shionogi Research Laboratories, Shionogi Co. Ltd., Osaka, 553, Japan

SOURCE: Journal of Medicinal Chemistry (1998), 41(4), 640-649

CODEN: JMCMAH; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 193809-82-4P 193809-84-6P 193809-85-7P 193809-89-1P 193809-94-8P 193809-98-2P 193810-07-0P 193810-11-6P 193810-14-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unassisted); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Preparation of N-sulfonylamino acid derivs. as orally active type IV collagenase inhibitors)

RN 193809-82-4 CAPLUS

CN D-Valine, N-[[4-[2-(4-methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193809-84-6 CAPLUS

CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 193809-85-7 CAPLUS

CN D-Phenylalanine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193809-89-1 CAPLUS

CN D-Valine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193809-94-8 CAPLUS

CN D-Tryptophan, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 193809-98-2 CAPLUS

CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193810-07-0 CAPLUS

CN D-Phenylalanine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193810-11-6 CAPLUS

CN D-Phenylalanine, N-[[4-[2-(4-cyclohexylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 193810-14-9 CAPLUS

CN D-Tryptophan, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 193810-45-6P 203639-61-6P 203639-79-6P 203639-92-3P 203640-02-2P 203640-28-2P 203640-30-6P 203640-31-7P 203640-32-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-sulfonylamino acid derivs. as orally active type IV collagenase inhibitors)

RN 193810-45-6 CAPLUS

CN D-Valine, N-[[4-[2-(4-methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 203639-61-6 CAPLUS

CN D-Tryptophan, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


# 10824057 - Compound Search

L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 203639-79-6 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 203639-92-3 CAPLUS  
CN D-Valine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 203640-02-2 CAPLUS  
CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 203640-28-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203640-30-6 CAPLUS  
CN D-Phenylalanine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 203640-31-7 CAPLUS  
CN D-Phenylalanine, N-[[4-(2-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 203640-32-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-cyclohexylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1997:513624 CAPLUS  
DOCUMENT NUMBER: 127:162119  
TITLE: Preparation of N-sulfonylamino acid derivatives as metalloproteinase inhibitors  
INVENTOR(S): Watanabe, Fumihiko; Tsuruki, Hiroshige; Ohtani, Mitsuaki  
PATENT ASSIGNEE(S): Shionogi and Co., Ltd. Japan  
SOURCE: PCT Int. Appl., 1997, pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727174	A1	19970731	WO 1997-JP126	19970122
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN			
RW:	KE, LS, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2242416	A1	19970731	CA 1997-2242416	19970122
CA 2242416	C	20060321		
CA 2483020	A1	19970731	CA 1997-2483020	19970122
AU 9713195	A	19970820	AU 1997-13195	19970122
AU 715764	B2	20000210		
CN 1214041	A	19990414	CN 1997-193226	19970122
BR 9707010	A	19990720	BR 1997-7010	19970122
EP 950656	A1	19991020	EP 1997-900747	19970122
EP 950656	B1	20070411		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
HU 9903687	A2	20000328	HU 1999-3687	19970122
HU 9903687	A3	20011228		
HU 226006	B1	20080228		
NZ 325939	A	20000623	NZ 1997-325939	19970122
SK 282995	B6	20030109	SK 1998-984	19970122
RU 2198656	C2	20030220	RU 1998-115659	19970122
EP 1486207	A2	20041215	EP 2004-21556	19970122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, AL			
JP 3628335	B2	20050309	JP 1997-526728	19970122
AT 359264	T	20070515	AT 1997-900747	19970122
ES 2284180	T3	20071101	ES 1997-900747	19970122
CZ 298814	B6	20080213	CZ 1998-2252	19970122
TW 575547	B	20040211	TW 1997-86100862	19970127
TW 244474	B	20051201	TW 2003-92127003	19970127
TW 244475	B	20051201	TW 2003-92128956	19970127
NO 9803376	A	19980914	NO 1998-3376	19980722
NO 312665	B1	20020617		
US 6150394	A	20001121	US 1998-120378	19980722
US 6207698	B1	20010327	US 1998-120197	19980722
US 6919375	B1	20050719	US 1998-120383	19980722
US 6235768	B1	20010522	US 1999-307818	19990510
AU 738793	B2	20010927	AU 2000-30222	20000501
US 6441021	B1	20020827	US 2000-710904	20001114
JP 2001316254	A	20011113	JP 2001-69135	20010312
JP 3795339	B2	20060712		
US 20030139379	A1	20030724	US 2002-188115	20020703

# 10824057 - Compound Search

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
 US 6881727 B2 20050419  
 US 20030225043 A1 20031204 US 2002-290245 20021108  
 US 6838483 B2 20050104  
 JP 2006232839 A 20060907 JP 2006-55044 20060310  
 JP 1996-30082 A 19960123  
 JP 1986-213555 A 19960813  
 CA 1997-2242416 A3 19970122  
 EP 1997-900747 A3 19970122  
 EP 1997-526728 A3 19970122  
 WO 1997-JF126 W 19970122  
 US 1998-120197 A3 19980722  
 US 1998-120383 A1 19980722  
 US 2000-710904 A3 20001114  
 JP 2001-69135 A3 20010312

OTHER SOURCE(S): MARPAT 227:162119  
 IT 193809-82-4P 193809-84-6P 193809-85-7P  
 193809-86-8P 193809-87-9P 193809-88-0P  
 193809-89-1P 193809-90-2P 193809-91-5P  
 193809-92-6P 193809-93-7P 193809-94-8P  
 193809-95-9P 193809-96-0P 193809-97-1P  
 193809-98-2P 193809-99-3P 193810-00-3P  
 193810-01-4P 193810-02-5P 193810-03-6P  
 193810-04-7P 193810-05-8P 193810-06-9P  
 193810-07-0P 193810-08-1P 193810-09-2P  
 193810-10-5P 193810-11-6P 193810-12-7P  
 193810-13-8P 193810-14-9P 193810-15-0P  
 193810-16-1P 193810-17-2P 193810-18-3P  
 193810-19-4P 193810-20-7P 193810-26-3P  
 193810-27-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of sulfonilamino acid derivs. as metalloproteinase inhibitors)  
 RN 193809-82-4 CAPLUS  
 CN D-Valine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193809-84-6 CAPLUS  
 CN D-Tryptophan, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193809-85-7 CAPLUS  
 CN D-Phenylalanine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193809-86-8 CAPLUS  
 CN Tryptophan, 1-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 193809-87-9 CAPLUS  
 CN Tryptophan, 5-fluoro-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)



L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 193809-88-0 CAPLUS  
 CN D-Leucine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 193809-89-1 CAPLUS  
 CN D-Valine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193809-90-4 CAPLUS  
 CN Tryptophan, 4-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)




RN 193809-91-5 CAPLUS  
 CN [1,1'-Biphenyl]-4-propanoic acid,  $\alpha$ -[[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]amino]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 193809-92-6 CAPLUS  
 CN 1-Naphthalenepropanoic acid,  $\alpha$ -[[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]amino]- (CA INDEX NAME)



PAGE 1-A

PAGE 2-A




RN 193809-93-7 CAPLUS  
 CN D-Tryptophan, 1-formyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




# 10824057 - Compound Search

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193809-94-8 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193809-95-9 CAPLUS  
CN D-Isoleucine, N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 193809-96-0 CAPLUS  
CN D-Isoleucine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193809-97-1 CAPLUS  
CN D-Valine, N-[[4-[2-(4-hydroxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)

Absolute stereochemistry.



RN 193809-98-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193809-99-3 CAPLUS  
CN D-Valine, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA  
INDEX NAME)


Absolute stereochemistry. Rotation (-).

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-00-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-3-  
methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-01-4 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193810-02-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]-  
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-03-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-(trifluoromethyl)phenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 193810-04-3 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-nitrophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-05-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




# 10824057 - Compound Search

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 193810-06-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-chlorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 193810-07-9 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193810-08-1 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-09-2 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-cyanophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-13-8 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-hydroxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-14-9 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-bromophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193810-15-0 CAPLUS  
CN D-Tryptophan, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-10-5 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-(1,1-dimethylethyl)phenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-11-6 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-cyclohexylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193810-12-7 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-(4-phenoxyphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-16-1 CAPLUS  
CN D-Valine, N-[[4-[2-(4-methylphenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-17-2 CAPLUS  
CN D-Valine, N-[[4-[2-(4-fluorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 193810-18-3 CAPLUS  
CN D-Valine, N-[[4-[2-(4-chlorophenyl)-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-19-4 CAPLUS  
CN D-Phenylalanine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 193810-20-7 CAPLUS  
CN D-Tryptophan, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 193810-26-3 CAPLUS  
CN D-Valine, N-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 193810-27-4 CAPLUS  
CN D-Leucine, N-methyl-N-[[4-(2-phenyl-2H-tetrazol-5-yl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 193810-45-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of sulfonylamino acid derivs. as metalloproteinase inhibitors)  
RN 193810-45-6 CAPLUS  
CN D-Valine, N-[[4-[2-[4-(methylthio)phenyl]-2H-tetrazol-5-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:453940 CAPLUS  
DOCUMENT NUMBER: 127:65789  
TITLE: Preparation of piperazino- or piperidinobenzenesulfonamides as inhibitors of matrix metalloproteinases  
INVENTOR(S): Ortwine, Daniel Fred; Purchase, Claude Forsey, Jr.; White, Andrew David  
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Ortwine, Daniel Fred; Purchase, Claude Forsey Jr.; White, Andrew David  
SOURCE: Int. Appl., 76 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY NO. COUNT: 2  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719068	A1	19970529	WO 1996-US16761	19961018
W: AU, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KR, LK, LR, LS, LT, LV, MG, MK, MN, MM, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2233560	A1	19970529	CA 1996-2233560	19961018
CA 2233560	C	20051220		
AU 9674641	A	19970611	AU 1996-74641	19961018
AU 727569	B2	20001214		
EP 874836	A1	19981104	EP 1996-936718	19961018
EP 874836	B1	20021009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9611487	A	19990119	BR 1996-11487	19961018
HU 9902083	A2	19991028	HU 1999-2083	19961018
HU 9902083	A3	20000628		
JP 2000514779	T	20001107	JP 1997-519715	19961018
NZ 321293	A	20010427	NZ 1996-321293	19961018
AT 225779	T	20021015	AT 1996-936718	19961018
SK 282833	B6	20021203	SK 1998-641	19961018
FT 874836	T	20030228	PT 1996-936718	19961018
CZ 291659	B6	20030416	CZ 1998-1467	19961018
ES 2184893	T3	20030416	ES 1996-936718	19961018
IL 123901	A	20030624	IL 1996-123901	19961018
ZA 9609584	A	19970602	ZA 1996-9584	19961114
US 5977141	A	19991102	US 1998-68726	19980513
BG 63967	B1	20030829	BG 1998-102448	19980513
NO 9802223	A	19980515	NO 1998-2223	19980515
NO 310231	B1	20010611		
US 6297247	B1	20011002	US 2000-599306	20000622
PRIORITY APPLN. INFO.:			US 1995-7372P	P 19951117
			WO 1996-US16761	W 19961018
			US 1999-412707	A3 19991005

OTHER SOURCE(S): MARPAT 127:65789  
IT 191474-97-2P 191475-00-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of piperazino- or piperidinobenzenesulfonamides as inhibitors of matrix metalloproteinases)  
RN 191474-97-2 CAPLUS  
CN L-Tyrosine, O-(phenylmethyl)-N-[[4-(4-phenyl-1-

23 APR 2008


L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 191475-00-0 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(3-methoxyphenyl)-1-piperazinyl]phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 191474-88-1P 191474-89-2P 191474-90-5P  
191474-91-6P 191474-92-7P 191474-93-8P  
191474-98-3P 191474-99-4P 191475-01-1P  
191475-02-2P 191475-03-3P 191475-04-4P  
191475-05-5P 191475-06-6P 191475-07-7P  
191475-09-9P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of piperazino- or piperidinobenzenesulfonamides as inhibitors of matrix metalloproteinases)  
RN 191474-88-1 CAPLUS  
CN D-Leucine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.


# 10824057 - Compound Search

L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 191474-89-2 CAPLUS  
CN L-Leucine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 191474-90-5 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 191474-91-6 CAPLUS  
CN D-Phenylalanine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 191474-92-7 CAPLUS  
CN L-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 191474-93-8 CAPLUS  
CN Benzenepentanoic acid,  $\alpha$ -[[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 191474-98-3 CAPLUS  
CN L-Tyrosine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 191474-99-4 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-phenyl-1-piperazinyl)phenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 191475-01-1 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(3-hydroxyphenyl)-1-piperazinyl]phenyl]sulfonyl]-, monohydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HBr

RN 191475-02-2 CAPLUS  
CN L-Phenylalanine, N-[[4-[4-(4-methoxyphenyl)-1-piperazinyl]phenyl]sulfonyl]- (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 191475-03-3 CAPLUS  
CN Benzenebutanoic acid,  $\alpha$ -[[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 191475-04-4 CAPLUS  
CN L-Cysteine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]-S-(triphenylmethyl)-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


RN 191475-05-5 CAPLUS  
CN D-Tryptophan, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

23 APR 2008

# 10824057 - Compound Search


L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● 2 Na

RN 191475-06-6 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl]sulfonyl]-, (CA INDEX NAME)


Absolute stereochemistry.



RN 191475-07-7 CAPLUS  
CN L-Phenylalanine, N-[[4-(4-(4-chlorophenyl)-1-piperazinyl)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




● HCl

RN 191475-09-9 CAPLUS  
CN L-Cysteine, N-[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 191475-08-8  
CMF C20 H24 N2 O4 S2

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



L3 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1988:529608 CAPLUS  
DOCUMENT NUMBER: 109:129608  
ORIGINAL REFERENCE NO.: 109:21621a, 21624a  
TITLE: Functionalization of tetrakis(p-sulfonylphenyl)porphyrin and its tin(IV) derivative with amino acid esters  
AUTHOR(S): Bedel-Cloutour, Catherine H.; Rama, Abdelmoula  
CORPORATE SOURCE: Lab. Chim.Org. Organometall., Univ. Bordeaux I, Talence, F-33405, Fr.  
SOURCE: Main Group Metal Chemistry (1987), 10(1), 45-55  
CODEN: MGMC88, ISSN: 0792-1241  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 116249-28-6P 116249-22-6P 116275-48-0P  
116393-91-0P 116393-92-1P 116417-98-2P  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
RN 116249-22-6 CAPLUS  
CN Tin dichloro[[tetrakis(4,1-phenylenesulfonyl)]tetrakis(L-leucinato)] (2-)-N21,N22,N23,N24]-, (OC-6-12)- (9CI) (CA INDEX NAME)


PAGE 1-A



# 10824057 - Compound Search


L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 116249-29-7 CAPLUS  
CN Tin, dichloro[[tetraethyl N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis[L-phenylalaninato]](2-)-N21,N22,N23,N24]-, (OC-6-12)- (9CI) (CA INDEX NAME)

PAGE 1-A




L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B

— Ph


PAGE 2-A




RN 116275-48-0 CAPLUS  
CN Tin, dichloro[[tetraethyl N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis[L-phenylalaninato]](2-)-N21,N22,N23,N24]-, (OC-6-12)- (9CI) (CA INDEX NAME)

L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 116393-91-0 CAPLUS  
CN L-Leucine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis-, tetraethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B

— OEt

— Bu-i

PAGE 2-A




# 10824057 - Compound Search

L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 116393-92-1 CAPLUS  
CN L-Alanine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis-, tetraethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B




PAGE 2-A



L3 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 2-A



RN 116417-98-2 CAPLUS  
CN L-Phenylalanine, N,N',N'',N'''-[21H,23H-porphine-5,10,15,20-tetrayltetrakis(4,1-phenylenesulfonyl)]tetrakis-, tetraethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

